Metabolite Profiling in Anticancer Drug Development: A Systematic Review

Nadda Muhamad1
Kesara Na-Bangchang1,2,3

1Chulabhorn International College of Medicine, Thammasat University, Pathum Thani 12120, Thailand; 2Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University, Pathum Thani 12120, Thailand; 3Drug Discovery and Development Center, Office of Advanced Sciences and Technology, Thammasat University, Pathum Thani 12120, Thailand

Abstract: Drug metabolism is one of the most important pharmacokinetic processes and plays an important role during the stage of drug development. The metabolite profile investigation is important as the metabolites generated could be beneficial for therapy or leading to serious toxicity. This systematic review aims to summarize the research articles relating to the metabolite profile investigation of conventional drugs and herb-derived compounds for cancer chemotherapy, to examine factors influencing metabolite profiling of these drugs/compounds, and to determine the relationship between therapeutic efficacy and toxicity of their metabolites. The literature search was performed through PubMed and ScienceDirect databases up to January 2019. Out of 830 published articles, 78 articles were included in the analysis based on pre-defined inclusion and exclusion criteria. Both phase I and II enzymes metabolize the anticancer agents/herb-derived compounds. The major phase I reactions include oxidation/hydroxylation and hydrolysis, while the major phase II reactions are glucuronidation, methylation, and sulfation. Four main factors were found to influence metabolite formation, including species, gender, and route and dose of drug administration. Some metabolites were identified as active or toxic metabolites. This information is critical for cancer chemotherapy and anticancer drug development.

Keywords: metabolism, metabolite profile, anticancer, herbal medicine, cancer

Introduction
Cancer remains the major cause of death globally. In 2018, approximately 18 million new cases and 9 million deaths from cancer were estimated to occur worldwide.1 Several chemotherapeutic agents have been developed for treatment and prevention of cancer, either chemically synthetic drugs or herb-derived compounds.2–6 As herb-derived anticancer drugs are considered to be less toxic compared with synthetic drugs, attentions to developing new drugs originating from herbal products have substantially been paid worldwide. These include leelamine, the natural active compound from the bark of pine tree,7 atractyloidin and β-eudesmol, the natural active compounds from rhizomes of Atractylodes lancea (Thunb) DC,8 and alantolactone, an active sesquiterpene from Inula helenium L.9

Drug metabolism and pharmacokinetic (DMPK) studies play an important role in all steps of drug discovery and development, including anticancer drugs.10 Metabolism is the process of which xenobiotics or endogenous substances in the body are bio-transformed to the metabolic products that facilitate their elimination.11 Drug metabolism involves two main phases, i.e., phase I and phase II metabolism. The primary enzyme system involved in phase I metabolism is cytochrome P450 (CYP), and the
major enzymes involved in phase II are UDP-glucuronosyltransferase (UGT), sulfotransferase (SULT), glutathione-S-transferase (GST), N-acetyltransferase (NAT), and methyltransferase (MT). Drug metabolism plays a crucial role in determining the efficiency and safety of drugs. Drugs undergo metabolism to form numerous stable metabolites, most of which are pharmacologically inactive. On the other hand, in some cases, metabolism may lead to reactive metabolites that can induce adverse effects. Various types of drug metabolism studies have been incorporated during the process of drug discovery and development to generate new chemical entities (NCE) with acceptable safety profiles. This is particularly important for cancer chemotherapeutic drugs with a narrow therapeutic window. Metabolite profiling and identification studies of these compounds and currently used drugs are therefore essential. The main aim of metabolic profiling studies is to identify metabolic pathways and metabolites generated from the biotransformation process. The information obtained from the studies would help to optimize lead compounds for optimal pharmacokinetic and pharmacodynamic properties. Besides, it will help to identify new chemical entities based on the metabolites generated to minimize potential safety liabilities due to the formation of reactive or toxic metabolites. Comparison of information obtained from preclinical studies in animals and humans would also ensure potential adequate coverage of human metabolites in animals and for supporting human prediction.

This systematic review aimed to summarize the research articles relating to the metabolite profiling studies of anticancer drugs (conventional chemical synthetic drugs and targeted small-molecules) and candidate compounds from herbal sources. Factors influencing metabolite profiles (metabolic pathways and types of metabolites generated) and their relationship with anticancer activity and toxicity in vitro, in vivo (animals), and human were also investigated.

Materials and Methods
Study Selection and Inclusion and Exclusion Criteria
This systematic review was performed through the search from PubMed (via Endnote) and ScienceDirect databases up to January 2019. The following keywords were used: “anticancer drug”, “anticancer agent”, “chemotherapy”, “chemotherapeutic drug”, “traditional medicine”, herbal medicine, “natural compound”, “metabolism”, “metabolite profile”, “metabolite identification”, “metabolite characterization”, and “cancer”. No other search conditions were applied. All articles obtained from the two databases were checked for duplication. The remaining articles were initially screened as per the inclusion criteria based on the content of the abstract section. The inclusion criteria for article selection were 1) articles in full-texts and written in English; 2) articles with the investigation (in vitro, in vivo, or clinical studies) of metabolite profiles of conventional chemotherapeutic drugs, small molecules targeted therapy, candidate synthetic anticancer agents, natural products-derived anticancer compounds or drug candidates. The duplicates, review articles, short communications, case reports, articles with the investigation of other types of drug metabolism studies, or those with insufficient information of metabolite(s) or metabolic pathway(s) were excluded from data analysis.

Data Extraction and Collection
Two independent researchers performed data extraction from all articles. When conflicting opinions arose, the decision was sought from higher professional level personnel, and the decision was considered final. The title and abstract of each article search from PubMed (via Endnote) and ScienceDirect databases using the keywords mentioned above were initially screened for relevant original articles based on the inclusion and exclusion criteria. The full-text articles were carefully examined to confirm their compliance with the defined eligibility criteria. The studies of metabolite profile of chemotherapeutic drugs, targeted small molecules, candidate synthesized anticancer agents, traditional or herbal medicines, and natural compounds for cancer were classify according to types of anticancer agents. The information extracted included: name of anticancer drug or compound/herb, type of studies (in vitro, in vivo, and clinical studies), gender and species of animals used, route and dose of administration of the investigated drugs/compounds, biochemical tools used (liver, prostate, intestine, or kidney microsomes, subcellular fractions, hepatocytes, recombinant enzymes, and whole blood), type of biological samples (plasma, urine, bile, feces, and tumor), and study conclusion.

Results
Study Description
Three hundred and twenty-one out of 830 articles were duplicated or review articles and were initially excluded.
from the analysis. The title and abstract were further screened based on eligible criteria, and 411 articles were further excluded from the analysis. Finally, 78 out of 98 articles were included in the analysis; 20 excluded articles were case reports, short communications, and articles with insufficient information. The flow diagram of the search process is presented in Figure 1. Information on metabolite profiles including biochemical tools/biological samples used in the studies of conventional anticancer drugs, synthetic anticancer candidates, small molecules targeted therapy, herb-derived compounds with anticancer activities are summarized in Tables 1–3, respectively and the anticancer activities of each compound are presented in Table 4.

Out of 78 articles included in the analysis (42 in vitro, 42 in vivo, and 16 clinical studies), 47 (60.3%), 14 (17.9%) and 17 (21.8%) articles respectively, investigated metabolite profiles of conventional anticancer drugs/synthetic anticancer candidates, small-molecules targeted therapy, and herb-derived compounds with anticancer activities. These studies involved a total of 57 (57.0%) conventional anticancer drugs/synthetic anticancer candidates, 22 (22.0%) studies for small-molecules targeted therapy, and 21 (21.0%) studies for herb-derived compounds with anticancer activities (Tables 1–3). Anticancer drugs or candidate compounds are metabolized by either Phase I, or Phase II metabolizing enzyme alone, or both phase I and phase II metabolizing enzymes. The major metabolic pathways of phase I reaction include oxidation/hydroxylation and hydrolysis. The major metabolic pathways of phase II reaction are glucuronidation, methylation, and sulfation (Tables 1–3).

Several factors were found to influence the metabolite profiles of these drugs/compounds, including species, gender, and route and dose of administration. Relationship between the generated metabolites and anticancer activity and/or toxicity were reported in 10 (17.5%) studies for conventional anticancer drugs/synthetic anticancer candidates, 1 (4.5%) studies for small-molecules targeted therapy, and 4 (19.0%) studies for herb-derived compounds with anticancer activities.

Discussion

The goals of conducting drug metabolism studies are to identify and characterize all major metabolites of the investigated drugs and specific enzymes responsible for their metabolism; to evaluate the impacts of the metabolites on safety and efficacy of the drug, and to utilize the drug metabolism information to maximize their intellectual property. The identity of metabolites present in any matrix of animal or human provides essential information about the biotransformation pathways involved in the clearance of a drug. Technological advances during the past decade have greatly improved analytical capabilities to detect, identify, and characterize metabolites at previously unattainable levels. Chromatography and electrophoresis are usually methods of choice. Electrospray ionization (ESI) and atmospheric pressure chemical ionization (APCI) liquid chromatography-mass spectrometry (LC/MS) have become ideal methods of choice. This is due to its superior specificity, sensitivity, and...
| Anticancer Drug | Type of Study | Biochemical Tool/Animal/ Human (Route: Dose) | Type of Sample | Analytical Technique | Outcome | Metabolic Pathway | Efficacy/Toxicity of Metabolite |
|-----------------|---------------|---------------------------------------------|----------------|----------------------|---------|------------------|---------------------------------|
| AM6–36 (3-amino-6- (3′-aminopropyl)-5H-indeno[1,2-c] isoquino[5,11-(6H) dione) | In vitro | HLM, human hepatocyte | – | HPLC- QTOF-MS, HPLC-QqQ-MS | 1 Metabolite for HLM (4); 7 Metabolites for hepatocyte (4–10) | Reduction (4); Monoacetylation (5); Conversion of amino acid group to an alcohol (7); Reduction of the ketone to an alcohol + conversion of amino acid group to an alcohol (8); Reduction + acetylation (6); Monoacetylation + conversion of amino acid group to an alcohol (9); Glucuronidation (10) | Metabolites 5: lower retinoid X receptor (RXR) homodimers bind to DNA response elements (RXRE) induction activity than parent compound AM6-36. Metabolites 8: exhibited lower activity to inhibit NFKB than AM6-36 |
| ARQ 501 (synthetic β-lapachone) | In vitro | Mouse, rat, dog, monkey, human whole blood | – | UPLC- QTOF-MS, HPLC-MS-ARC | 4 Metabolites for mouse and rat (M1, M2, M3, M5); 5 Metabolites for dog (M1, M2, M3, M5, unidentified metabolite); 5 Metabolites for monkey (M1, M2, M3, M5, M6); 6 Metabolites for human (M1, M2, M3, M4, M5, M6); ARQ 501 disappeared after 60 min of incubation in human whole blood | Oxidation (M1); Adding 2 oxygen and 2 hydrogen atoms (M2); Adding 1 oxygen and 2 hydrogen atoms (M3); Loss of 1 carbon atom (M4 and M6); Loss of CO group (M5) | Not evaluated |
| ARQ 501 (synthetic β-lapachone) | In vivo | Mice (IP: 40 mg/kg), rats (IV: 40 mg/kg) | Plasma | LC-QTOF-MS, HPLC-QqQ-MS | 3 Metabolites for all species | Glucosylation + sulfation; Glucuronidation; Sulfation | Not evaluated |
| | Clinical trial | Cancer patients (140 mg/m²) | – | | 3 Metabolites | | |

**Table 1** Metabolism Studies (Metabolite Profiling) of Conventional Synthetic Anticancer Drugs
| Drug       | Phase I clinical trial | Advanced solid tumor patients (IV: 25 mg/m² of [14C]-cabazitaxel (50 μCi, 1.85 MBq of [14C]-cabazitaxel)) | Plasma, urine, feces | HPLC-RD-MS | 6 Metabolites in plasma (Major: RPR123142); 10 Metabolites in urine (Major: M09b); 13 Metabolites in feces (Major: RPR104943, RPR 104952, RPR111026, RPR 111059) | 7-O-demethylation + 10-O-demethylation + hydroxylation (RPR104952); 10-O-demethylation (RPR123142); 7-O-demethylation + 10-O-demethylation + di-hydroxylation (M09b); 7-O-demethylation + di-hydroxylation + 10-O-demethylation (RPR111026, RPR111059); 7-O-demethylation + di-hydroxylation + 10-O-demethylation + hydroxylation (RPR104943); Cleavage is minor pathway plasma and urine | Not evaluated | [16] |
|------------|------------------------|-------------------------------------------------------------------------------------------------|---------------------|------------|------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------|------------------|
| Cabazitaxel| In vivo                | Male Wistar rats (PO: 80 mg/kg)                                                                | Bile, urine, liver, kidneys | HPLC-TIS-MS/MS, 19F-, NMR and 1H-NMR | 3 Metabolites for liver (5'-deoxy-5-fluorocytidine, α-Fluoro-β-alanine, 2'-(β-D-glucuronic acid)-5'-deoxy-5-fluorocytidine); 2 Metabolites for bile (5'-deoxy-5-fluorocytidine, 2'-(β-D-glucuronic acid)-5'-deoxy-5-fluorocytidine); 2 Metabolites for kidney (5'-deoxy-5-fluorocytidine, α-Fluoro-β-alanine); 4 Metabolites for urine (5'-deoxy-5-fluorouridine, 5,6-Dihydro-5-fluorouracil, α-Fluoro-β-alanine, 5'-deoxy-5-fluorocytidine) | Glucuronidation (2'-(β-D-glucuronic acid)-5'-deoxy-5-fluorocytidine); Not identified (5'-deoxy-5-fluorocytidine, α-fluoro-β-alanine, 5'-deoxy-5-fluorouridine, 5,6-Dihydro-5-fluorouracil) | Not evaluated | [17] |
| Capecitabine| In vivo                | Male Wistar rats (PO: 80 mg/kg)                                                                | Bile, urine, liver, kidneys | HPLC-TIS-MS/MS, 19F-, NMR and 1H-NMR | 3 Metabolites for liver (5'-deoxy-5-fluorocytidine, α-Fluoro-β-alanine, 2'-(β-D-glucuronic acid)-5'-deoxy-5-fluorocytidine); 2 Metabolites for bile (5'-deoxy-5-fluorocytidine, 2'-(β-D-glucuronic acid)-5'-deoxy-5-fluorocytidine); 2 Metabolites for kidney (5'-deoxy-5-fluorocytidine, α-Fluoro-β-alanine); 4 Metabolites for urine (5'-deoxy-5-fluorouridine, 5,6-Dihydro-5-fluorouracil, α-Fluoro-β-alanine, 5'-deoxy-5-fluorocytidine) | Glucuronidation (2'-(β-D-glucuronic acid)-5'-deoxy-5-fluorocytidine); Not identified (5'-deoxy-5-fluorocytidine, α-fluoro-β-alanine, 5'-deoxy-5-fluorouridine, 5,6-Dihydro-5-fluorouracil) | Not evaluated | [17] |
### Table 1 (Continued).

| Anticancer Drug | Type of Study | Biochemical Tool/Animal/ Human (Route: Dose) | Type of Sample | Analytical Technique | Outcome | Metabolic Pathway | Efficacy/Toxicity of Metabolite | Ref. |
|-----------------|---------------|---------------------------------------------|----------------|----------------------|---------|------------------|-------------------------------|------|
| Carbenazim (2-benzimidazolecarbamic acid methyl ester) | In vitro | RLM, HLM | – | HPLC-ESI-MS | 1 Metabolite (5(6)- or 4(7)- hydroxyl carbendazim) | Oxidation | Not evaluated | [18] |
| | In vivo | Rats (PO: 1000 mg/kg) | Serum | | 1 Metabolite (2-aminobenzimidazole) | Hydrolysis | | |
| CI941 (losoxantrone) | In vitro | Rat hepatocyte, human hepatoblastoma (HepG2) cell lines | – | HPLC-UV, HPLC-QqQ-MS, 1H-NMR | 12 Metabolites (M2-M13) for rat hepatocyte; No metabolite in HepG2 | Hydroxylation (M2, M3); Hydroxylation + oxidation (M8); Hydroxylation + oxidation + glutathione conjugation (M10); Hydroxylation+ glucuronidation (M4, M9); Hydroxylation + sulfation (M5-M7); Oxidation (M11-M13) | Not evaluated | [19] |
| Cisplatin | In vivo | Male Sprague-Dawley rats (IV: 3mg/kg) | Kidney tissue | HPLC-ESI-QTOF-MS | 31 Metabolites (M1-M31) | Hydration (M1); Hydroxylation (M4); Dihydroxylation (M3); Methionine conjugation (M5); Di-methionine conjugation (M15, M29); Cysteine conjugation (M7, M8); Di-cysteine conjugation (M16, M31); Chlorination (M24, M26); Acetylcysteine conjugation (M9, M10); Di-acetylcysteine conjugation (M17); Glutathione conjugation (M11); Thioether conjugation (M13); Hydration+ hydroxylation (M2); Methionine conjugation + hydroxylation (M6); Methionine conjugation + chelation (M18, M20, M25); Methionine conjugation + chelation + hydroxylation (M19); Cysteine conjugation+ chelation (M21, M23, M27, M28, M30); Cysteine conjugation+ chelation + hydroxylation (M22); Glutathione conjugation +hydroxylation (M12); Thioether conjugation + hydroxylation (M14); | Not evaluated [20] |

(Continued)
| Anticancer Drug | Type of Study | Biochemical Tool/Animal/Human (Route: Dose) | Type of Sample | Analytical Technique | Outcome | Metabolic Pathway | Efficacy/Toxicity of Metabolite | Ref. |
|----------------|---------------|---------------------------------------------|----------------|---------------------|---------|------------------|-------------------------------|-----|
| CP-31398 (N'-(2,2-(4-methoxyphenyl)ethenyl)-4-quinazolinyl)-N,N-dimethyl-1,3-propanediamine dihydrochloride) | In vivo | Male and Female CD rats (PO: 0, 240, 480, or 960 mg/m²/day) and beagle dogs (0, 200, 400, or 800 mg/m²/day) | Plasma | HPLC-QTOF-MS | 4 Metabolites for rat (II: hydroxy CP-31398, III: O-demethyl CP-31398, IV: N-demethyl CP-31398, V: hydroxy O-demethyl CP-31398); 4 Metabolites for dog (II: hydroxy CP-31398, III: O-demethyl CP-31398, IV: N-demethyl CP-31398, V: di-demethyl CP-31398) | Hydroxylation (hydroxy CP-31398); O-demethylation (O-demethyl CP-31398); N-demethylation (N-demethyl CP-31398); Hydroxylation + O-demethylation (hydroxy O-demethyl CP-31398); Di-demethylation (di-demethyl CP-31398) | Not evaluated | [21] |
| CPA (Cyproterone acetate) | In vivo | Female Wistar-Han rats (PO: 50 mg/kg [3H] CPA (0.42 MBq/mg)) | Bile | HPLC-MS, GC-MS, 1H-NMR | 2 Metabolites (M1: 3α-OH-CPA and M2) | Sulfation and/or Glucuronidation | 3α-OH-CPA covalently bound to guanine which might be the major adduct formed of CPA | [22] |
| Crisnatol | In vitro | Human hepatoma (Hep G2) cells, HLM | – | GC-MS, 1H-NMR | 3 Metabolites for Hep G2 (M1 and M2: isomeric crisnatol dihydrodiol and M3: crisnatol 1,2-dihydrodiol); 2 Metabolites for HLM (M4: crisnatol 1,2-dihydrodiol and M5: 1-hydroxycrisnatol) | Di-hydroxylation + di-hydrogenation (M3, M4); Hydroxylation (M5) | Not evaluated | [21] |
| Cyclophosphamide | Clinical trial | Cancer patients (60 mg/kg) | Plasma, urine | GC-MS | 1 Active metabolite for both samples (N, N-bis(2-chloroethyl) phosphorodiamidic acid) | Not identified | Not evaluated | [24] |
| Substance | Form | In vitro | Pooled | HPLC-ESI-MS/MS | Metabolites | Demethylation | Oxidation | Bisoxidation | Isomerization | Not evaluated | Ref. |
|-----------|------|----------|--------|---------------|-------------|---------------|-------------|--------------|---------------|--------------|------|
| DFS       | 2,6-| In vitro | Pooled MLM, RLM, HLM | 10 Metabolites for MLM (M1-10); 7 Metabolites for RLM (M1, M3-6, M9-10); 6 Metabolites for HLM (M1-3, M5, M7, M10) | Demethylation (M1); Oxidation (M2-M4); Demethylation + Oxidation (M5); Oxidation + Defluorination (M6, M7); Bisoxidation (M8, M9); Isomerization (M10) |  |
|           | difluoro-4′-(N, N)-dimethylamino) stilbene: Stilbene analog | | | | | | | | | | [25] |
| 5′-dFUR  | 5′-deoxy-5′-fluorouridine | In vivo | Cancer patients (IV: 4 g/m²) | Plasma | 3 Metabolites (N³-Methylated-5′-dFUR, 5-fluorouracil, and 5,6-dihydro-5-fluorouracil) | Methylation (N³-Methylated-5′-dFUR); Not identified (5-fluorouracil, and 5,6-dihydro-5-fluorouracil) |  |
| 5′-dFUr | 5′-deoxy-5′-fluorouridine | Clinical trial | Cancer patients (IV: 10 g/m²) | Blood, plasma, urine | 19F-NMR | 4 Metabolites in blood and plasma (5-fluorouracil, α-fluoro-β-ureidopropionic acid, α-fluoro-β-alanine, 5,6-dihydrofluorouracil); 3 Metabolites in urine (5-fluorouracil, α-fluoro-β-ureidopropionic acid, α-fluoro-β-alanine) | Not identified |  |
| EAPB0203 | In vitro | Pooled RLM, DLM | | HPLC-MS/MS (QqQ and QTOF), 1H-NMR, 13C-NMR | 4 Metabolites for DLM (EAPB0202, M7, M2, and M1); 6 Metabolites for RLM (EAPB0202, M7, M6, M3, M2, M1) | Hydroxylation (M1-M3, M6, M7); Demethylation (EAPB0202) |  |
|           | | | | | | | | | | | [28] |

(Continued)
| Anticancer Drug | Type of Study | Biochemical Tool/Animal/ Human (Route: Dose) | Type of Sample | Analytical Technique | Outcome  | Metabolic Pathway | Efficacy/Toxicity of Metabolite | Ref. |
|-----------------|---------------|---------------------------------------------|----------------|----------------------|----------|------------------|---------------------------------|-----|
| EAPB0503 (imiquimod analogs) and EAPB0502 (M^7) and EAPB0603 (M^5) (active metabolites of EAPB0503) | In vitro | MLM, RLM, DLM, HLM; Rat, dog, and human hepatocyte | — | LC-ESI-MS/MS | EAPB0503:  6 Metabolites for MLM (M^2-M^7); 4 Metabolites for RLM (M^2, M^4, M^5, M^7); 7 Metabolites for DLM (M^1-M^7); 4 Metabolites for HLM (M^2, M^4, M^5, M^7); 4 Metabolites for rat hepatocyte (M^2, M^4, M^5, M^7); 5 Metabolites for dog hepatocyte (M^1, M^2, M^4, M^6, M^7); 4 Metabolites for human hepatocyte (M^2, M^4, M^5, M^7)  EAPB0502: 2 Metabolites for MLM (M^2 and M^3); 2 Metabolites for RLM (M^2 and M^3); 2 Metabolites for DLM (M^2 and M^3); 1 Metabolite for HLM (M^2); 1 Metabolite for rat hepatocyte (M^3)  EAPB0603: 2 Metabolites for MLM (M^1, M^2); 1 Metabolite for RLM (M^2); 2 Metabolites for DLM (M^1, M^2); 1 Metabolite for HLM (M^2); 1 Metabolite for dog hepatocyte (M^1) | O-demethylation (M^5); N-demethylation (M^7); Hydroxylation (M^4, M^6); O- and N-demethylation (M^2); N-demethylation + hydroxylation (M^3); Hydroxylation + O-demethylation (M^1) | Not evaluated | [29] |
| Substance                  | In vitro | RLM (Aroclor 1254-treated), PLM | Method              | Metabolites                                                                 | Toxicity                                                                 |
|---------------------------|----------|---------------------------------|---------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------|
| E-DE-BPH (E-3,4-bis(4-Ethylphenyl) hex-3-ene: stilbene derivatives) | In vitro | RLM (Aroclor 1254-treated), PLM | HPLC-UV, GC-MS, GC-IR | 5 Metabolites for Aroclor 1254-treated RLM (M1: 3,4-bis-(4-(1-hydroxyethyl) phenyl) hex-3-ene, M2: E-3-(4-acetylphenyl)-4-(4-(1-hydroxyethyl) phenyl) hex-3-ene, M3: E-3,4-bis(4-acetylphenyl) hex-3-ene, M4: E-3-(4-(1-hydroxyethyl) phenyl)-4-(4-ethylphenyl) hex-3-ene, M5: E-3-(4-acetylphenyl)-4-(4-ethylphenyl) hex-3-ene); 4 Metabolites for PLM (M1, M2, M4, M5) | Not evaluated [30] |
| 2-F-araA (9-β-D-arabinofuranosyl-2-fluoroadenine) | In vivo  | Male BDF1 mice (IV: 400 mg/m²), female beagle dog (IV: 400 mg/m²), female rhesus monkey (IV: 400 mg/m²) | Urine, blood HPLC-MS | 1 Metabolite detected in dog blood (9-β-D-arabinofuranosyl hypoxanthine: 2-F-araH); 2 Metabolites for urine of all species (2-fluoroadenine: 2-F-ad, 2-F-araH) | Not identified [31] |

(Continued)
Table 1 (Continued).

| Anticancer Drug | Type of Study | Biochemical Tool/Animal/Human (Route: Dose) | Type of Sample | Analytical Technique | Outcome | Metabolic Pathway | Efficacy/Toxicity of Metabolite | Ref. |
|-----------------|---------------|-------------------------------------------|----------------|----------------------|---------|------------------|--------------------------------|------|
| Flutamide       | In vitro      | Male human, male dog, and male rat liver microsomes Male pig liver and prostate microsomes | –              | LC-ESI-QTOF-MS      | Liver microsomes: 1 Metabolites for human (OH-Flu); 4 Metabolites for dog (Flu-1, OH-Flu (2 isoforms), M1, M3); 4 Metabolites for rat (Flu-1, OH-Flu (3 isoforms), M1, M3 (2 isoforms)); 4 Metabolites for pig (Flu-1, OH-Flu (2 isoforms), M1, M3) Prostate microsomes: 2 Metabolites for pig (OH-Flu, Flu-5) | Monohydroxylation (OH-Flu); Di-hydroxylation (M1); Tri-hydroxylation (M3); Sulfation (Flu-3 sulfate); Glucuronidation (Flu-3 glucuronide); Hydroxylation + mercapturic acid conjugation (hydroxyflutamide mercapturic acid); Hydroxylation + glucuronidation (hydroxyflutamide glucuronide); Di-hydroxylation + glucuronidation (M1 glucuronide) | Formation of a mercapturic acid conjugate from flutamide in human urine, suggesting that the reported liver effects of flutamide are due to the molecular mechanism caused by a reactive intermediate | [32] |
|                 | In vivo       | Prostate cancer patients (Oral: 250 mg BID) | Urine           |                      | 10 Metabolites (Flu-1, Flu-3, Flu-3 sulfate, Flu-3 glucuronide, OH-Flu, M1, M3, hydroxyflutamide mercapturic acid, hydroxystevanamide glucuronide, M1 glucuronide) | | | |
| 4-Hydroxyanisole| In vivo       | Malignant melanoma patients (IA: 80 g)    | Urine           | GC-MS                | 4 Metabolites (1: hydroquinone, 3: 3,4-dihydroxyanisole, 4: 3-methoxy-4-hydroxyanisol, and 5: 4-hydroxy-3-methoxyanisole) | Methylated metabolites might be conjugated with glucuronic acid or sulphates | Not evaluated | [31] |
| Drug     | In vitro         | Metabolism                  | Phase I and II clinical trials                                                                 | Urine                                                                 | Clinical trial | Metabolism                  | Phase I and II clinical trials                                                                 | Urine                                                                 |
|----------|------------------|-----------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|----------------|-----------------------------|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Irinotecan | HLM, recombinant CYP enzymes (1A1, 1A2, 2C8, 2C9, 3A4, 3A5, and 3A7) | 4 Metabolites for cells expressing CYP3A4 (M1, NPC, M2, APC); 5 Metabolites for microsomes containing CYP3A4 and CYP3A5 (M1, NPC, M2, APC, M4); 1 Metabolite for cells expressing CYP3A5 (M4); No metabolite for cells expressing CYP2C8, CYP2C9, CYP1A1, CYP1A2, and CYP3A7 | Cavum carcinoma patient (IV: 300 mg/m²), brain tumor patient (600 mg/m²), glioblastoma patients (350 mg/m³) | 7 Metabolites (SN-38-G, M1, NPC, M2, M3, APC, SN-38) | Cancer patients (IV: 70 mg; 80 nCi) | HPLC-AMS, LC-MS | 3 Degradants and 4 metabolites for plasma and urine (Deg-1–Deg-3, M8, M16, M19, M41); 3 Degradants and 3 metabolites for feces (Deg-1–Deg-3, M8, M19, M41) | Plasma, urine, feces | Dehydration (Deg-1–Deg-3); Dehydration + oxygenation (M41); Hydroxylation (M8); Oxygenation + dehydrogenation (M16); Oxygenation + dehydration (M19) | Not evaluated [34] |
| Ixabepilone | Clinical trial | 3 Degradants and 4 metabolites for plasma and urine (Deg-1–Deg-3, M8, M16, M19, M41); 3 Degradants and 3 metabolites for feces (Deg-1–Deg-3, M8, M19, M41) | | | | HPLC-AMS, LC-MS | | Dehydration (Deg-1–Deg-3); Dehydration + oxygenation (M41); Hydroxylation (M8); Oxygenation + dehydrogenation (M16); Oxygenation + dehydration (M19) | Not evaluated [35] |
Table 1 (Continued).

| Anticancer Drug | Type of Study | Biochemical Tool/Animal/Human (Route: Dose) | Type of Sample | Analytical Technique | Outcome | Metabolic Pathway | Efficacy/Toxicity of Metabolite | Ref. |
|-----------------|---------------|--------------------------------------------|----------------|----------------------|---------|-------------------|-------------------------------|-----|
| JM216 (bis (acetato) ammine-dichloro (cyclohexylamine) Platinum (IV)) | Phase 1 clinical trial | Cancer patients (PO: 120, 200, 300, 420, 540 mg/m²) | Plasma | HPLC-MS | 6 Platinum metabolites (A, JM383, JM559, D, JM118, F) | Hydrolysis + declorination (JM518, JM559); Di-hydrolysis + di-declorination (JM383); Hydrolysis + declorination + reduction + clorination (JM118); Hydrolysis + declorination + reduction + glutathione conjugation + methylation (A) | JM118: higher cytotoxic activity against 8 human ovarian carcinoma cell lines (HX 62, SKOV-3, CH1, CH1 CISR, 41M, 41M CISR, A2780 A2780 CISR) compared to JM216 and cisplatin JM518 and JM383: similar and less cytotoxic activity to JM216 | [36] |
| JM216 (bis (acetato) ammine-dichloro (cyclohexylamine) Platinum (IV)) | In vitro | Human plasma | Plasma | HPLC-UV, LC-MS | 5 Platinum metabolites (A, JM383, JM559, JM518, JM118) | Not evaluated | Not evaluated | [37] |
| K02 (Morpholine-urea-Phe-Hphe-vinylsulfone) | In vitro | HLM, cDNA-expressed CYP3A4 | – | HPLC-RD | 3 Major metabolites for both (M12, M19, M20) | Hydroxylaton | Not evaluated | [38] |
| Laromustine | In vitro | RLM, DLM, HLM, MLM | – | HPLC-RD | 7 Similar metabolites for all species but in different quantity (C1-C7: C4 = major metabolite) | Demethylsufoxidation; Hydrolysis; Oxidation | Not evaluated | [38] |
| 2-Methoxyestradiol | In vitro | Pooled HLM | – | HPLC, HPLC-QqQ-MS | 4 Phase I metabolites (A, B, C, D); 2 Phase II metabolites (G1, G2) | Hydroxylation (A, B, C, D); Glucuronidation (G1, G2) | Not evaluated | [39] |
| 2-Methoxyestradiol | In vivo | Cancer patients (PO: 800 mg or 2200 mg BID) | Urine | HPLC | 2 Phase II metabolites (G1, G2) | Glucuronidation (G1, G2) | Not evaluated | [39] |
| Compound          | Route | Species | Tissue | Method          | Metabolites                                    | Additional Remarks                        | Literature |
|-------------------|-------|---------|--------|-----------------|------------------------------------------------|-------------------------------------------|------------|
| Mitomycin C       | In vivo | Murine  | Tumor  | HPLC-UV         | 4 Metabolites (trans-hydro, cis-hydro, 2,7-diaminomitosene, decarbamoyl 2,7-DM) | Hydrolysis (trans-hydro, cis-hydro); Reduction (2,7-DM); Reduction + decarbamoyl (decarbamoyl 2,7-DM) | [40]       |
| NB-506            | In vivo | Male Sprague-Dawley rat | Bile    | HPLC-RD-MS, ¹H NMR, ¹³C NMR | 3 Metabolites (RBM-1, RBM-2, ED501) | Deformyl metabolite (ED501); 0-glucuronidation (RBM-1); ED501 + glucuronidation (RBM-2) | Not evaluated [41] |
| 9NC (9-nitro-20(S)-camptothecin) | In vivo | Wistar rats | Bile, urine, feces | LC-IT-MS, LC-QTOF-MS (M2, M5 and M7), ¹H NMR | 5 Metabolites for bile (M1, M2, M3, 9-AC, M4, 9-AA-CPT, M5); 3 Metabolites for urine (M1, M3, M6); 3 Metabolites for feces (M4, M6, M7: 9-OH-CPT) | Glucuronidation of 9-OH-CPT (M1); Loss of glutamic acid from MS (M2); Reduction (M3); Acetylation (M4); Glutathione conjugate of 10-OH-CPT (M5); Mercapturic acid conjugate of 10-OH-CPT (M6); Aglycone of M1 (M7) | Not evaluated [42] |
| NSC 141549 (4ʹ-(9-Acridinylamino)methanesulfon-m-anisidine (m-AMSA)) | In vivo | Male Sprague-Dawley rats | Plasma (IV), bile (IP) | HPLC-MS | 1 Major metabolite for plasma (4-amino-3-methoxymethanesulfonilide); 1 Major metabolite for bile (9-acridinyl thioether of glutathione) | Methoxylation (4-amino-3-methoxy methanesulfonilide); Glutathione conjugation (9-acridinyl thioether of glutathione) | Not evaluated [43] |

(Continued)
| Anticancer Drug                          | Type of Study | Biochemical Tool/Animal/Human (Route: Dose) | Type of Sample | Analytical Technique | Outcome Metabolite | Metabolic Pathway | Efficacy/Toxicity of Metabolite | Ref. |
|-----------------------------------------|---------------|---------------------------------------------|----------------|----------------------|--------------------|-------------------|--------------------------|------|
| NSC 652287 (2,5-bis(5-hydroxymethyl-2-thienyl) furan) | In vitro     | Dog liver S9 fraction                       | –              | GC-MS                | 1 Major metabolite | Methylation or oxidation | Not evaluated             | [44] |
| NSC 674495 (2-(4-Amino-3-methylphenyl) benzothiazole: DF 203) | In vitro     | Breast cancer cell lines (MCF-7, T-47D, and MDA-MB-435) and renal cancer cell lines (TK-10, A498, and CAKI-1) | –              | HPLC-spectrofluorometry, 1H NMR | 1 Major metabolite for sensitive cell lines (T-47D, MDA-MB-435): 6c: 2-(4-amino-3-methylphenyl)-6 hydroxybenzothiazole | Hydroxylation | 6c: low anti-cancer activity against MCF-7 cell lines (IC50>100 M) | [45] |
| PAC-1 (4-benzyl-piperazin-1-yl)-acetic acid (3-allyl-2-Hydroxy-benzylidene)-hydrazine | In vivo     | Male Wistar rats (PO: 50 mg/kg)             | Urine, feces, bile | HPLC-QTOF-MS, HPLC-IT-MS | 14 Metabolites for urine (M1-M7, M9-M11, M13-M16); 3 Metabolites for feces (M1, M6, M13); 4 Metabolites for bile (M4, M13, M14, M16) | Debenzylation (M1); Hydroxylation (M2-M6); Dihydroxylation (M8-M12); Carboxylation (M7); Dihydrodiol formation (M13); Glucuronidation (M14); Hydroxylation + glucuronidation (M15-M16) | Not identified | [46] |
| Paclitaxel                   | In vivo      | Ovarian carcinoma patients (IV: 135 mg/m²) | Plasma, urine    | HPLC-MS              | 2 Metabolites for plasma (P1: 6α-hydroxypaclitaxel, P3: 7-eipaclitaxel); 3 Metabolites for urine (U1: 6α-hydroxypaclitaxel, U2: 10-deacetylpaclitaxel, U4: 7-eipaclitaxel) | Not identified | Not evaluated | [47] |
| Compound    | Type        | Species/Conditions                              | Method     | Metabolites                                                                 | Reference |
|-------------|-------------|-------------------------------------------------|------------|------------------------------------------------------------------------------|-----------|
| Paclitaxel  | In vitro    | Liver microsomes from: Sprague-Dawley & hairless rats (males, females), BALB/c & OF1 mice (males, females), male guinea-pigs, male rabbits, male dogs, male monkeys, and humans | HPLC-UV    | 1 Metabolite for male & female SD and hairless RLM, male & female BALB/c MLM (3′p-hydroxypaclitaxel); 2 Metabolites for male & female OF1 mice & male rabbits (6α-hydroxypaclitaxel and 3′p-hydroxypaclitaxel); 2 Metabolites for male dog (6α-hydroxypaclitaxel, 6α,3′p-dihydroxypaclitaxel) liver microsomes; 3 Metabolites in male guinea-pigs, male monkey, human liver microsomes (6α-hydroxypaclitaxel, 3′p-hydroxypaclitaxel, 6α,3′p-dihydroxypaclitaxel) | [48]      |
|             | In vivo     | Male Dunkin Hartley albino guinea-pigs (IV: 6 mg/kg) | Bile       | 2 metabolites (M1: 6α-Hydroxypaclitaxel, M2: 3′p-Hydroxypaclitaxel)          |           |
| Phenylbutyrate | Clinical trial | Human (PO: 0.36 mmol/kg (5 g/75 kg)) | Plasma, urine | GC-MS | 3 Metabolites for both samples (phenylacetate, phenylacetylglutamine, phenylbutyrylglutamine) | Not identified | Not evaluated | [49]      |
| Phyllanthoside | In vivo    | Male CDF1 mice                                | Plasma     | HPLC-UV | 1 Metabolite (M)                | Aglycone | M: anticancer activity against human rhabdomyosarcoma cell lines (A204 cell lines) lower than parent compound with IC_{50} of 24 µM and 0.47 nM | [50]      |
| Anticancer Drug | Type of Study | Biochemical Tool/Animal/Human (Route: Dose) | Type of Sample | Analytical Technique | Outcome | Metabolic Pathway | Efficacy/Toxicity of Metabolite | Ref. |
|----------------|---------------|---------------------------------------------|----------------|----------------------|---------|------------------|--------------------------------|-----|
| Sepin-1        | In vitro     | MLM, RLM, HLM                              | –              | UHPLC-QTOF-MS        | 7 Metabolites for all species (M1-M7) | Reduction (M1, M2); Dimer formation (M3-M5); Cysteine conjugation (M6); Glutathione conjugation (M7) | Not evaluated | [51] |
| SN30000 (3-(3-Morpholinopropyl)-7,8-dihydro-6H-indeno[5,6-e] [1,2,4] triazine 1.4-dioxide: tirapazamine analog) | In vivo     | Female NIH-III mice (IP: 186 mg/kg) | Plasma, liver, HT29 tumor | LC-MS/MS | 19 Metabolites for plasma (M1-M19); 16 Metabolites for liver (M3-M7, M9, M10-M19); 19 Metabolites for tumor (M1-M19) | Reduction; Oxidation; Glucuronidation | M14: acute toxicity (hypothermia) similarly to SN30000 | [6] |
| Tamoxifen      | In vivo     | Athymic mice (PO and SC: 200 mg/kg/day, 50 mg/kg/day, and 12.5 mg/kg/day), Breast cancer patients (10 mg BID) | Serum          | HPLC-UV              | 2 Metabolites for mouse serum after PO and SC of 200 mg/kg/day and 50 mg/kg/day and patient serum (4-Hydroxytamoxifen and N-desmethyl tamoxifen); Higher level of metabolites with higher doses | Hydroxylation (4-Hydroxytamoxifen); N-demethylation (N-desmethyl tamoxifen) | Not evaluated | [52] |
| Tamoxifen      | In vitro     | Human liver homogenate, human hepatoblastoma (HepG2) cell lines | –              | LC-ESI-MS            | 6 Metabolites for human liver homogenate (M1-M5, M8); 4 Metabolites for HepG2 (M2-M5) | N-Di-desmethylation (M1); N-Desmethylation (M4); Hydroxylation (M2 and M3); N-oxidation (M5); N-Desmethylation + hydroxylation (M6, M7); N-oxidation + hydroxylation (M8) | Not evaluated | [53] |
| Tamoxifen | In vivo | Female Rowett athymic nude rats (PO: 5 mg/kg/day or SC: 50 mg) | Serum, liver, lung, retroperitoneal adipose tissue, kidneys, brain, muscle, heart, spleen, stomach, small intestine, uterus tissues | 2 Metabolites for all samples except adipose tissue (4-Hydroxytamoxifen, N-Desmethyltamoxifen) after 21 days PO; 4-Hydroxytamoxifen for all samples except adipose tissue and uterus after 33 days PO; N-Desmethyltamoxifen for all samples except adipose tissue after 33 days PO; 2 Metabolites for liver, lung, brain, heart, and kidney (4-Hydroxytamoxifen and N-Desmethyltamoxifen) after 33 days SC; Level of metabolites detected in SC lower than PO | Hydroxylation (4-Hydroxytamoxifen); Demethylation (N-Desmethyltamoxifen) | Not evaluated | [54] |

(Continued)
| Table 1 (Continued). |
|----------------------|
| **Anticancer Drug**  | Tamoxifen |
| **Type of Study**    | Clinical trial |
| **Tool/Animal Human (Route: Dose)** | Breast cancer patients (PO: 20–40 mg/day) |
| **Type of Sample**   | Plasma |
| **Analytical Technique** | UHPLC-QqQ-Quantum, MS and UHPLC-Exactive Plus, Orbitrap-MS |
| **Outcome**          | 40 Metabolites (1–23, 25–27, 29–36, 38, 39, 42–45) |
| **Efficacy/Toxicity of Metabolite** | Not evaluated |
| **Ref.**             | [55] |
| **Analytical Technique** | UHPLC-QqQ-Quantum, MS and UHPLC-Exactive Plus, Orbitrap-MS |
| **Type of Sample**   | Plasma |
| **Outcome**          | 40 Metabolites (1–23, 25–27, 29–36, 38, 39, 42–45) |
| **Efficacy/Toxicity of Metabolite** | Not evaluated |
| **Ref.**             | [55] |

- Metabolites
- Tamoxifen
- Clinical trial
- Breast cancer patients (PO: 20–40 mg/day)
- Plasma
- UHPLC-QqQ-Quantum, MS and UHPLC-Exactive Plus, Orbitrap-MS
- 40 Metabolites (1–23, 25–27, 29–36, 38, 39, 42–45)
- Not evaluated
- [55]
| Compound | Clinical trial | Advanced solid tumor patients (PO: 1000 nCi of $^{14}$C-TPI) | Plasma, urine, feces | HPLC-QqQ-MS | Major metabolites for plasma, urine, and feces (6-hydroxymethyluracil (6-HMU)) | Not identified | Not evaluated |
|----------|----------------|-------------------------------------------------------------|---------------------|-------------|--------------------------------------------------------------------------------|--------------|--------------|
| TAS-102 (tipiracil hydrochloride (TPI) + trifluridine (FTD)) | Advanced solid tumor patients (PO: 200 nCi of $^{14}$C-FTD) | 1 Major metabolite for plasma, urine, and feces (6-hydroxymethyluracil (6-HMU)) | Glucuronidation (FTD Glu U3 and FTD Glu U4); Unidentified (FTY) |

| Compound | Clinical trial | Plasma, urine, feces | HPLC-QqQ-MS | Major metabolites for plasma (Trifluoromethyluracil (FTY)); Major metabolites for urine (FTY, FTD Glu U3, FTD Glu U4) | Not identified | Not evaluated |
|----------|----------------|---------------------|-------------|--------------------------------------------------------------------------------|--------------|--------------|
| TNP-470 (O-(chloroacetyl-carbamoyl) fumagillol) | In vitro | Human hepatocyte, human liver, intestinal, kidney microsomes | 6 Metabolites for cultured human hepatocytes (M1-M6: M2 and M5 = predominant metabolites of extracellular and intracellular, respectively); 3 Metabolites for HLM (M1, M2, M4); 2 Metabolites for intestine and kidney microsomes (M2, M4) | Esterase (M4); Esterase + Epoxide hydrolysis (M2) | Not evaluated |

| Compound | Clinical trial | Plasma (rat) and urine (pig) | HPLC | Major metabolites for pig urine (TW-01003 sulfate); Metabolites for rat plasma after IV (TW-01003 sulfate (major), TW-01003 glucuronide); Metabolites after PO (TW-01003 sulfate, TW-01003 glucuronide (major)) | Sulfation (TW-01003 sulfate); Glucuronidation (TW-01003 glucuronide) | Not evaluated |
|----------|----------------|-----------------------------|-----|--------------------------------------------------------------------------------|--------------|--------------|
| TW01003 ((3E,6E)-3-Benzylidene-6-[5-(5-hydroxypyridin-2-yl)methylene] piperazine-2,5-dione) | In vivo | Pig (IV) and male Wistar rats (IV: 7 mg/kg and PO: 36 mg/kg) | 1 Metabolite for pig urine (TW-01003 sulfate); 2 Metabolites for rat plasma after IV (TW-01003 sulfate (major), TW-01003 glucuronide); 2 Metabolites after PO (TW-01003 sulfate, TW-01003 glucuronide (major)) | Sulfation (TW-01003 sulfate); Glucuronidation (TW-01003 glucuronide) | Not evaluated |

**Abbreviations:** AMS, Accelerator Mass Spectrometry; ARC, Accurate Radioisotope Counting; DLM, Dog Liver Microsome; ESI, Electro spray Ionization; GC, Gas Chromatography; HLM, Human Liver Microsome; HPLC, High Performance Liquid Chromatography; I.R, Infrared spectroscopy; IP, Intraperitoneal; IT, Ion trap; IV, Intravenous; LC, Liquid Chromatography; MLM, Monkey Liver Microsome; MS, Mass Spectrometry; NMR, Nuclear Magnetic Resonance spectroscopy; PLM, Pig Liver Microsome; PO, Per oral; QqQ, Triple quadrupole; QTOF, Quadrupole Time-of-flight; RD, Radio Detection; RLM, Rat Liver Microsome; SC, Subcutaneous; TIS, Turbo Ion Spray; UHPLC, Ultra-High Performance Liquid Chromatography; UPLC, Ultra Performance Liquid Chromatography; UV, Ultraviolet detection.
| Anticancer Drug | Type of Study | Biochemical Tool/Animal/Human (Route: Dose) | Type of Sample | Analytical Technique | Outcome | Metabolic Pathway | Efficacy/Toxicity of Metabolite | Ref. |
|----------------|--------------|------------------------------------------|----------------|---------------------|---------|-----------------|--------------------------------|------|
| AZD8055        | In vitro     | RLM                                      | –              | UHPLC-IT-MS         | 5 Metabolites (M1-M5) | Demethylation (M1); Hydroxylation (M2); Oxidation (M3 and M4); Di-oxidation (M4); Morpholine ring opened AZD8055 (M5); Demethylation + glucuronidation (M6); Hydroxylation + glucuronidation (M7); Glucuronidation (M8) | Not evaluated | [59] |
|                | In vivo      | Male Sprague-Dawley rat (PO: 20 mg/kg)   | Plasma, urine, feces |                     | 8 Metabolites in all samples (M1-M8) | | | | |
| Brivanib       | In vitro     | Pooled HLM and cytosol, human cDNA-expressed CYP, and human recombinant SULTs | – | HPLC-LTQ-IT-MS | 6 Metabolites (M7, M19, M25, M26, M31 M33) | Hydroxylation (M7); Oxidation (M26, M31); Sulfation (M25); Oxidation + sulfation (M19, M33) | Not evaluated | [60] |
| **EPZ-5676**  
| (Pinometostat) | **In vitro** | RLM, DLM, HLM, and rat, dog, and human hepatocyte | - | HPLC-RD-IT-TOF-MS | 6 Metabolites for RLM  
| EPZ007769, EPZ007309, M3, M4, M6, M8);  
| 1 Metabolite for DLM  
| EPZ007769);  
| 5 Metabolites for HLM  
| EPZ007769, EPZ007309, M3, M4, M6);  
| 7 Metabolites for rat hepatocyte  
| EPZ007769, EPZ007309, M1a/b, M2, M3, M6, M8);  
| 4 Metabolites for dog hepatocyte  
| EPZ007769, EPZ007309, M1a/b, M2);  
| 5 Metabolites for human hepatocyte (EPZ007769, EPZ007309, M1a/b, M2, M6) | Mono-hydroxylation (EPZ007769);  
| Mono-hydroxylation + oxidation (EPZ026194);  
| Dealkylation of N-isopropyl (EPZ007309);  
| N-dealkylation + tri-oxidation (M1a/b);  
| N-dealkylation + di-oxidation (M2);  
| N-dealkylation + mono-oxidation (M3);  
| N-dealkylation + keto-oxidation (M4);  
| Mono-oxidation + dehydrogenation (M5);  
| Mono-oxidation (M6 and M7);  
| N-dealkylation + hydroxylation (M8);  
| N-dealkylation (M9, M10 and M11);  
| Oxidative cleavage of ribose ring (M12);  
| N-dealkylation + oxidation (M13) | Not evaluated | [61] |
| **In vivo** | Sprague–Dawley rats (IV: 30 mg/kg/day (100 µCi/kg)) and Beagle dogs (IV: 10 mg/kg/day (200 µCi/animal)) | Plasma, urine, feces, bile (rat and dog) | Plasma, urine, feces, bile (rat and dog) | 2 Metabolites for rat plasma  
| EPZ007769, EPZ026194);  
| 3 Metabolites for rat urine  
| EPZ007769, EPZ026194, M5);  
| 2 Metabolites for dog urine  
| EPZ007769, EPZ026194);  
| 4 Metabolites for rat feces  
| EPZ007769, EPZ026194, M7, M9);  
| 4 Metabolites for dog feces  
| EPZ007769, EPZ026194, M7, M8);  
| 4 Metabolites for rat bile  
| EPZ007769, EPZ026194, M5, M6);  
| 2 Metabolites for dog bile  
| EPZ007769, EPZ026194) | Mono-hydroxylation (EPZ007769);  
| Mono-hydroxylation + oxidation (EPZ026194);  
| Dealkylation of N-isopropyl (EPZ007309);  
| N-dealkylation + tri-oxidation (M1a/b);  
| N-dealkylation + di-oxidation (M2);  
| N-dealkylation + mono-oxidation (M3);  
| N-dealkylation + keto-oxidation (M4);  
| Mono-oxidation + dehydrogenation (M5);  
| Mono-oxidation (M6 and M7);  
| N-dealkylation + hydroxylation (M8);  
| N-dealkylation (M9, M10 and M11);  
| Oxidative cleavage of ribose ring (M12);  
| N-dealkylation + oxidation (M13) | Not evaluated | [61] |
| **Phase I clinical trial** | Cancer patient (IV: 36 mg/m² day) | Plasma, urine | Plasma, urine | 2 Metabolites for plasma  
| EPZ007769, EPZ007309);  
| 10 Metabolites for urine  
| EPZ007769, EPZ007309, M1a/b, M2, M8-M13) | Mono-hydroxylation (EPZ007769);  
| Mono-hydroxylation + oxidation (EPZ026194);  
| Dealkylation of N-isopropyl (EPZ007309);  
| N-dealkylation + tri-oxidation (M1a/b);  
| N-dealkylation + di-oxidation (M2);  
| N-dealkylation + mono-oxidation (M3);  
| N-dealkylation + keto-oxidation (M4);  
| Mono-oxidation + dehydrogenation (M5);  
| Mono-oxidation (M6 and M7);  
| N-dealkylation + hydroxylation (M8);  
| N-dealkylation (M9, M10 and M11);  
| Oxidative cleavage of ribose ring (M12);  
| N-dealkylation + oxidation (M13) | Not evaluated | [61] |
Table 2 (Continued).

| Anticancer Drug | Type of Study | Biochemical Tool/Animal/ Human (Route: Dose) | Type of Sample | Analytical Technique | Outcome | Metabolic Pathway | Efficacy/Toxicity of Metabolite | Ref. |
|-----------------|--------------|-------------------------------------------|----------------|---------------------|---------|------------------|--------------------------------|------|
| HM781-36B (1-[4-[4- (3,4-dichloro-2- fluorophenylamino)-7- methoxyquinazolin-6- yloxy]-piperidin-1-yl] prop-2-en-1-one hydrochloride) | In vivo | Male beagle dogs (PO: 8 mg/kg) | Urine, feces, plasma | HPLC-UV, LC-ESI-T-MS, LC-QTOF-MS/MS | 4 Metabolites for plasma (M1, M2, M8, M10); 3 Metabolites for urine and feces (M1, M2, M10) | Di-hydroxylation (M1); Demethylation (M2); N-Oxidation (M3, M9); Defluorination + hydroxylation (M4); Dechlorination + hydroxylation (M5); Dehydroxylation + di-hydroxylation (M6); N-oxidation + di-hydroxylation (M7); Hydroxylation (M8); Deacryloylpiperideine (M10) | Not evaluated | [5] |
| | In vitro | DLM, HLM, Recombinant CYP enzymes (3A4, 2D6, 1A2, 2C9, 2C19, and 2E1) | – | HPLC-LTQ-MS | 6 Metabolites (N-demethyl-, Unk#3, Unk#5, Unk#6, Unk#7, Unk#8) for CYP3A4; 4 Metabolites for CYP1A1 (N-demethyl-, Unk#3, Unk#5, Unk#7); 1 Metabolite for 1A2 (7); 2 Metabolites for 1B1 (5 and 7); 2 Metabolites for 4F2 (N-demethyl- and 5); 2 Metabolites for 4F3A and 4F3B (N-demethyl- and 5) | N-demethylation (N-demethyl-); Hydroxylation (Unk#3 and Unk#5); N-oxidation (Unk#6, Unk#7, and Unk#8) | Not evaluated | [62] |
| Imatinib | In vitro | Insect-cell microsomes that contained cDNA expressing human CYP isozymes (CYPI1A1, 1A2, 1B1, 1F2, 4F3A/B, 3A4) | – | HPLC-LTQ-MS | 28 Metabolites (1–17, 19–24, 27–29, 32, 33) | Hydroxylation/N-oxidation (3, 8, 9, 11–14, 18, 19, 22–24, 32); Hydroxylation/N-oxidation + N-demethylation (7, 10, 16, 20); Glucuronidation (27–29, 33); Other (2, 6, 31) | Not evaluated | [63] |
| | Clinical trial | Cancer patients (PO: 400-800 mg) | Plasma | HPLC-ESI-QqQ-MS | 31 Metabolites (1–14, 16, 18–20, 22–33) | | | |
| Metabolites                                | RLM: 12 Metabolites for male (M7-M11, P-24, M13-M16, M18, 667-coumarin) & female (M7-M11, M13-M16, M18, P36, 667-coumarin); | Hydroxylation (M7, M9, M13, M14, M18); Desulfamoylation (667-coumarin); Hydroxylation + desulfamoylation (M8, M15, M16, and P-36); Hydroxylation + desulfamoylation + glucuronidation (M1, M2, and M12); Hydroxylation + desulfamoylation + sulfation (M17); Not identified (M11) |
|-------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| DLM: 14 Metabolites for male & female    | DLM: 14 Metabolites for male & female (P-14, M7-M10, P-23, P-24, M13-M16, M18, P-36, 667-coumarin);                | Not evaluated                                                                                                                                                                                        |
| MLM: 9 Metabolites for male (P-14, M7- M10, P-24, M13, M14, M16); 8 Metabolites for female (P-14, M7-M10, P-24, M13, M16); | MLM: 9 Metabolites for male (P-14, M7-M10, P-24, M13, M14, M16); 8 Metabolites for female (P-14, M7-M10, P-24, M13, M16); |                                                                                                                                                                                                     |
| HLM: 14 Metabolites for male & female    | HLM: 14 Metabolites for male & female (M7-M11, P-23, P-24, M13-M16, M18, P-36, 667-coumarin);                     |                                                                                                                                                                                                     |
| Hepatocytes: 6 Metabolites for male rat (M2, M3, M7, M12, M17, 667-coumarin); 2 Metabolites for male dog (M12, M17); 7 Metabolites for female human (M1, M2, M12, M16, M17, 667-coumarin) | |                                                                                                                                                                                                     |

Continued
| Anticancer Drug | Type of Study | Biochemical Tool/Animal/Human (Route: Dose) | Type of Sample | Analytical Technique | Outcome | Ref. |
|----------------|--------------|--------------------------------------------|----------------|---------------------|---------|-----|
| JNJ-38877605   | In vitro     | Rat, rabbit, dog, monkey, and human hepatocytes and liver subcellular fractions | -              | LC-MS               | 12 Metabolites for all species hepatocyte and liver subcellular fraction (M1-M12) | M1-M5: crystal formation in kidney; M10: renal toxic metabolites in rabbit and human (species-specific toxic metabolite) |
|                | In vivo      | Rat (PO: 2.5 mg/kg), dog (PO: 2.5 mg/kg), and rabbit (PO: 100 mg/kg) | Plasma, urine, feces |                | 6 Metabolites for rat plasma, urine, feces (M1-M6); 4 Metabolites for dog plasma, urine, feces (M1-M4); 7 Metabolites for rabbit plasma, urine, feces (M2-M7, M10) | |
|                | Phase I clinical trial | Cancer patients (PO: 60 mg) | Plasma, urine |                | 4 Metabolites for human plasma and urine (M2, M3, M5, and M10) | |
|                |              |                                            |                |                   |                     | [65] |
| Lenvatinib | In vivo | Male Sprague Dawley rats (PO: 30 mg (12.685 MBq)/kg), Cynomolgus monkey (PO: 30 mg (12.685 MBq)/kg), and Solid tumor or lymphoma patients (PO: 24 mg (100 μCi)) | Plasma, urine, feces and bile | HPLC-LTQ-IT-MS, HPLC-LTQ-Orbitrap-MS | 27 Metabolites for rat (M1-M3, M5, MET5, MET6-MET8, MET10, MET12, MET15, MET17, MET18, MET19a, MET19b, MET20.1, MET21-MET24, MET24.1, MET27, MET29, MET29.1, MET30, MET32, MET34, MET35); 24 Metabolites for monkey (M1-M3, M2’, M3’, M5, MET3, MET4, MET9, MET10, MET13, MET16, MET18, MET20, MET20.1, MET22, MET23, MET24.1, MET26, MET27, MET29.1, MET30, MET32, MET34); 18 Metabolites for human (M1-M3, M2’, M3’, M5, MET3, MET4, MET20.1, MET22, MET24, MET27, MET29.1, MET30-MET32, MET34 MET36) | Oxidation/hydroxylation (M3’, MET34, MET35); Di-oxidation/Di-hydroxylation (MET36); N-oxidation (M3); Dealkylation (M1, M2); Hydrolysis (M5, MET30, MET32); Hydrolysis + oxidation/hydroxylation (MET29); Dealkylation + oxidation/hydroxylation (M2); Oxidation/hydroxylation + glucuronidation (MET31); Dealkylation + glucuronidation (MET27); Dealkylation + glucuronidation + hydrolysis (MET24); Hydrolysis/O-dearylation (MET29.1); Hydrolysis/O-dearylation + other conjugation (MET20.1, MET24.1); Glutathione/cysteine conjugation and subsequent biodegradation (MET7, MET8, MET10, MET12, MET13, MET15, MET18, MET19a, MET26); Glutathione/cysteine conjugation and subsequent biodegradation + intramolecular arrangement (MET19a and MET21); Glutathione/cysteine conjugation and subsequent biodegradation + intramolecular arrangement + dimerization (MET16, MET17, MET20, MET22, MET23); Glutathione/cysteine conjugation and subsequent biodegradation + intramolecular arrangement + glutathione/cysteine conjugation and subsequent biodegradation (MET3, MET4, MET6, MET9) | Not evaluated [66] |
| Anticancer Drug Type | Biochemical Tool/Animal/ Human (Route: Dose) | Type of Sample | Analytical Technique | Outcome | Metabolite | Metabolic Pathway | Efficacy/Toxicity of Metabolite | Ref. |
|----------------------|----------------------------------|----------------|---------------------|---------|------------|------------------|-------------------------------|------|
| Neratinib            | In vitro Rat hepatocytes          | -              | UHPLC-MS, UHPLC-DAD, Quadrupole-Orbitrap-MS | -       | 12 Metabolites (M1-M12); 6 Metabolites for urine (M3 and M8-M12) | - | G-Dealkylation + glutathione conjugation (M1, M3); G-Dealkylation (M3); Glutathione conjugation + G-dealkylation (M4, M5); Glutathione conjugation (M6, M7); Oxygenation + glutathione conjugation (M8); N-Acetylcysteine conjugation (M9, M11); N-demethylation (M10); N-oxygenation (M12); Glucuronidation | [67] |
| Neratinib            | In vivo Male Sprague-Dawley rats (PO: 20 mg/kg) | -              | UHPLC-MS, UHPLC-DAD, Quadrupole-Orbitrap-MS | -       | 12 Metabolites (M1-M12); 6 Metabolites for urine (M3 and M8-M12) | - | G-Dealkylation + glutathione conjugation (M1, M3); G-Dealkylation (M3); Glutathione conjugation + G-dealkylation (M4, M5); Glutathione conjugation (M6, M7); Oxygenation + glutathione conjugation (M8); N-Acetylcysteine conjugation (M9, M11); N-demethylation (M10); N-oxygenation (M12); Glucuronidation | [68] |
| Neratinib            | In vitro Colon cancer cell lines (drug resistant, colo-205, and drug sensitive, colo-320) | -              | UHPLC-MS, UHPLC-DAD, Quadrupole-Orbitrap-MS | -       | 7 Metabolites for HLM (DM-1: AZ5104, DM-2: AZ7550, OH-1, OH-2, OH-3, OH-4, OH-5); 4 Metabolites for MLM (DM-1, DM-2, OH-2, OH-4), | - | G-Dealkylation + glutathione conjugation (M1, M3); G-Dealkylation (M3); Glutathione conjugation + G-dealkylation (M4, M5); Glutathione conjugation (M6, M7); Oxygenation + glutathione conjugation (M8); N-Acetylcysteine conjugation (M9, M11); N-demethylation (M10); N-oxygenation (M12); Glucuronidation | [69] |
| Neratinib            | In vitro HLM, MLM | - | UHPLC-MS, UHPLC-DAD, Quadrupole-Orbitrap-MS | - | 2 Metabolites (M445, M554) | Oxidation (M445); Phosphoethanolamine conjugation (M554) | Not evaluated | [70] |
| Osimertinib          | In vitro Colo cancer cell line (drug resistant, colo-205, and drug sensitive, colo-320) | - | UHPLC-MS | - | 7 Metabolites for HLM (OH-1, OH-2, OH-3, OH-4, OH-5); 4 Metabolites for MLM (DM-1, DM-2, OH-2, OH-4), | - | Glucuronidation | Not evaluated |
| Osimertinib          | In vitro Colo cancer cell line (drug resistant, colo-205, and drug sensitive, colo-320) | - | UHPLC-MS | - | 7 Metabolites for HLM (OH-1, OH-2, OH-3, OH-4, OH-5); 4 Metabolites for MLM (DM-1, DM-2, OH-2, OH-4), | - | Glucuronidation | Not evaluated |
| Osimertinib          | Clinical trial Cancer patients (PO: 60 mg) | - | UHPLC-MS, Plasma, urine, and feces | - | 2 Metabolites (M445, M554) | Oxidation (M445); Phosphoethanolamine conjugation (M554) | Not evaluated | [70] |
| Pimasertib           | Clinical trial Cancer patients (PO: 60 mg) | - | UHPLC-MS, Plasma, urine, and feces | - | 2 Metabolites (M445, M554) | Oxidation (M445); Phosphoethanolamine conjugation (M554) | Not evaluated | [70] |
efficiency over other methods such as radioimmunoassay (RIA), gas chromatography/mass spectrometry (GC/MS), and liquid chromatography (LC) with ultraviolet detection (UV), fluorescence, radioactivity, and mass spectrometry (MS) detection. Most of the works in metabolite analysis were carried out using triple-quadrupole mass spectrometers. The main advantages include its superior quantitative capabilities in the multiple reaction monitoring (MRM) mode and the fact that a family of metabolites can easily be identified using neutral-loss and precursor ion scans.

Factors Influencing Metabolite Formation
Several factors were shown to influence metabolite formation of the parent drugs/compounds with anticancer activities. These included species, gender, and route and dose of administration of the parent drugs/compounds.

Species
Metabolic pathways and metabolite profiles of anticancer drugs/candidate compounds varied with animal species investigated. This is explained by the difference in the expression of metabolizing enzymes. For example, CYP1A1 and 1A2 enzymes are presented in mouse, rat, dog, monkey, and human, whereas CYP2C9, 2C19, 2D6, and 3A4 enzymes are only presented in human. In a study of flutamide (nonsteroidal antiandrogen used primarily for prostate cancer) metabolism, only one metabolite (designated OH-flu) was detected in human after incubation with human liver microsomes. On the other hand, four metabolites (Flu-1, OH-flu, M1, and M3) were detected after incubation of the compound with liver microsomes from rat, dog, and pig. Moreover, similar metabolite (OH-flu) was detected in rat and pig, but this metabolite was detected as 3 and 2 isoforms in rat and pig, respectively. For the synthetic β-lapachone, ARQ 501, similar phase I metabolites (M1-M3, and M5) were detected after incubation with whole blood of mouse, rat, dog, monkey, and human. On the other hand, only one phase I metabolite M4 was detected in human and M6 metabolite was detected in both human and monkey.

Gender
Gender is another factor that influences the metabolite profiles of anticancer drugs/candidate compounds due to difference in the expression levels of metabolizing enzymes between males and females. For example, in human, the levels of CYP2E1 and 1A2 are found to be higher in males than females, while the level of CYP3A4 is higher in...
| Anticancer Drug                          | Type of Study | Biochemical Tool/Animal/Human (Route: Dose) | Type of Sample | Analytical Technique | Outcome                                                                 | Metabolic Pathway                                                                 | Efficacy/Toxicity of Metabolite | Ref. |
|-----------------------------------------|---------------|---------------------------------------------|----------------|----------------------|--------------------------------------------------------------------------|---------------------------------------------------------------------------------|--------------------------------|------|
| Alantolactone (Inula helenium L.)      | In vivo       | Male Sprague–Dawley rats (PO: 100 mg/kg)    | Urine, feces, bile | UPLC-TOF-MS          | 11 Metabolites for urine (M1-M5, M10-M11, M14-M16, M18); 10 Metabolites for bile (M1-M4, M8, M12, M25, M33, M43-M44); 38 Metabolites for feces (M1-M13, M17-M25, M27-M31, M33, M35-M44) | Oxidation (M1-M9); Di-oxidation (M10-M11); Demethylation (M12-M13); Demethylation to carboxylic acid (M14-M15); Hydration (M16); Hydrogenation (M17-M18); Addition of H₂S (M19-M20); Addition of H₂S + oxidation (M21-M23); AL₂-S (M24-M25: one sulfur-containing dimer metabolites of alantolactone); AL₂-S + oxidation (M27-M31); AL₂SS (M33: two sulfur-containing dimer metabolites of alantolactone); AL₂SS + oxidation (M35-M39); AL₂SSS (M41: three sulfur-containing dimer metabolites of alantolactone); AL₂SSSS (M42: four sulfur-containing dimer metabolites of alantolactone); AL₂SSSSS (M44: five sulfur-containing dimer metabolites of alantolactone); Cysteine conjugation (M43); N-acetylcysteine conjugation (M44) | Not evaluated | [9]   |
| Astragalus Radix water extract (containing calycosin-7-β-glucoside, formononetin, calycosin, ononin, astragalin IV) | In vivo       | Male Sprague–Dawley rats (PO: 4 g/kg and 16 g/kg Astragalus Radix water extract) | Plasma         | UHPLC-MS/MS          | 4 Metabolites (calycosin-7-β-glucoside-3'-glucuronide for calycosin-7-β-glucoside, formononetin-3'-glucuronide for formononetin; calycosin-3'-glucuronide for calycosin, daidzein-3'-glucuronide); No metabolites for ononin and astragalin | Glucuronidation | Not evaluated | [71] |

Table 3: Metabolism Studies (Metabolite Profiling) of Herb-Derived Compounds with Anticancer Activities
| Compound                                      | In vitro | In vivo                  | LC-MS                  | Metabolite (after incubating liver microsomes with porcine esterase) | Breaking the ester bond | In vivo Metabolites | Not evaluated | In vivo Metabolites | Not evaluated |
|-----------------------------------------------|----------|--------------------------|------------------------|----------------------------------------------------------------------|-------------------------|---------------------|---------------|---------------------|---------------|
| Calphostin C (Cladosporium cladosporoides)    | CD-I MLM | Female CD-I mice (IP: 40 mg/kg) | Plasma                 | 1 Metabolite                                                        | Breaking the ester bond | 1 Metabolite       | Not evaluated |                    |               |
| CAT (3,6,7-trimethoxyphenanthroindolizidine (isolated from Typhora atrofolliculata)) | In vivo  | Male Wistar rats (PO: 6 mg/kg) | Urine                  | RRLC-ESI-QTOF-MS                                                    | Di-demethylation + di-glucuronidation (M1-M3); Di-demethylation + glucuronidation (M4-M9); Demethylation + glucuronidation (M10-M12); Di-demethylation (M13-M15); Demethylation (M16-M18); Oxidation (M19); Hydroxylation (M20-M21) | 21 metabolites (M1-M21) | Not evaluated |                    |               |
| Dimethoxycurcumin (Curcumin analog)          | In vitro | MLM (male CD-1), HLM (CYPexam) | HPLC-QTRAP, HPLC-QqQ-LIT-MS | 8 Metabolites for MLM (369, 371, 383, 399, 401, 559, 561); 7 Metabolites for HLM (369, 383, 385, 399, 401, 559, 561) | Di-O-demethylation (369); Di-O-demethylation + hydrogenation (371); O-demethylation (383); O-demethylation + hydrogenation (385); Hydrogenation (399); Di-hydrogenation (401); O-demethylation + glucuronidation (559); O-demethylation + hydrogenation + glucuronidation (561) | Not evaluated | Not evaluated |                    |               |
| Fisetin (flavonoid compound)                  | In vivo  | Female C57BL/6J mice (IP: 223 mg/kg) | Plasma                  | HPLC-MS/MS                                                          | Glucuronidation (M1, M2); Methoxylation (M3) | 3 Metabolites (M1, M2, M3: geraldol) | M3: 2.5 and 1.1-fold higher cytotoxic effect against LLC cell line (Lewis carcinoma) and EAhy 926 cell line (endothelial cell) compared to fisetin, respectively; M3 exhibited 1.5-fold fold higher cytotoxic effect against NIH 3T3 cell line (normal cell) | [72]           | [73]           | [74]           | [75]          | [76]           |
| Anticancer Drug | Type of Study | Biological Tool/Animal/ Human (Route: Dose) | Metabolite Pathway | Metabolic Pathway | Analytical Technique | Outcome |
|----------------|--------------|--------------------------------------------|-------------------|------------------|---------------------|---------|
| Flavone-8-acetic acid (FAA) | In vitro | HLM expressing CYP enzyme induced by Aroclor 1245 | 
6 Metabolites for HLM (M1, M2, M3, M4, M5, M6) <br> 3′,4′-dihydrodiol-FAA, M2: 3′-OH-FAA, M3: 3′,4′-epoxy-FAA, M4: 6-OH-FAA | 
Epoxide-hydrolase reaction (M1); Epoxidation (M2, M3); Hydroxylation (M3, M4, M5) | 
HPLC-UV, HPLC-UV-MS | 
6 Metabolites for MLM (M1: 3′,4′-dihydrodiol-FAA, M2: 5.6-epoxy-FAA, M3a: 4′-OH-FAA, M3b: 3′-OH-FAA, M4: 6-OH-FAA); One human liver microsome (sample 14) produced M3a and another human liver microsome (sample 15) produced 3 metabolites of M1, M3a: 3′,4′-epoxy-FAA, M3b: 4′-OH-FAA, M4: 6-OH-FAA | 
Interspecies difference in metabolism could involve with difference anticancer activity | 
[76] |
| Furanodiene (Rhizoma Curcumae) | In vitro | Rat liver S9, RLM | 
6 Metabolites for rat liver S9 (M1: 1β,10α,4α,5β-diepoxy-8α-hydroxy-glechoman-8α,12-olide, M2: 2β-hydroxyglycophthalide, M3: 14β,20β-dihydroxy-4β(1)-dien-8α,12-olide, M4: 1β,8β-dihydroxyeudesm-4,7(11)-dien-8α,12-olide or 1β,8β-dihydroxyeudesm-4,7(11),13-dien-8α,12-olide, M5: 1β,8β-dihydroxyeudesm-3,7(11),13-dien-8α,12-olide, M6: aegirosgeolide); 1 Metabolite for RLM (M6) | 
Oxidation (M6); Oxidation + Hydroxylation (M2, M3); Epoxidation (M1) | 
HPLC-ESI-MS, HR-ESI-MS, and 1H NMR, 13C NMR, 2D NMR | 
Not evaluated | 
[77] |
| In vivo | Male Sprague-Dawley Rat (PO: 100 mg/kg) | 
Bile, urine, feces | 1 Metabolite for bile and urine (M1-M6); 1 Metabolite for feces (M6) | | | |
| Metabolite | Methodology | Metabolite | Methodology |
|------------|-------------|------------|-------------|
| Grandisin (extracted from *Piper solmsianum*) | In vitro HLM – GC-MS and LC-MS | 4 Metabolites (M1: 4-O-demethylgrandis, M2: 4,4′-di-O-demethylgrandis, M3: 3,4-di-O-demethylgrandis, M4: 3-O-demethylgrandis) | Cleavage of methylene acetylene group (M1): Adding of hydroxy and methoxy groups (M2-M5) |
| | | Demethylation | Hydroxylation |
| Iris orientin (*Belamcanda chinensis*) | In vitro RLM – HPLC-UV | 7 Metabolites (M1: 6,7-Dihydroxy-5,3′,4′,5′-tetramethoxy isoflavone, M2: irigenin, M3: 5,7,4′-Trihydroxy-6,3′,5′-trimethoxy isoflavone, M4: 6,7,4′-Trihydroxy-5,3′,5′-trimethoxy isoflavone, M5: 6,7,5′-Trihydroxy-5,3′,4′-trimethoxy isoflavone, M6 and M7: unidentified) | Cleavage of methylene acetyl group (M1); Adding of hydroxyl and methoxy groups (M2-M5) |
| | | | Hydroxylation |
| Leelamine (bark of pine tree) | In vitro HLM | 1 Metabolite in the presence of NADPH generation system | Hydroxylation |
| | | | |
| Anticancer Drug | Type of Study | Biochemical Tool/Animal/Human (Route: Dose) | Type of Sample | Analytical Technique | Metabolic Pathway | Outcome | Efficacy/Toxicity of Metabolite |
|-----------------|---------------|------------------------------------------|---------------|---------------------|-------------------|---------|---------------------------------|
| MPD (Methyl protodioscin: isolated from Dioscorea collettii var. hypoglauca) | In vivo | Male Sprague-Dawley rat (PO: 80 mg/kg) | Urine | \( ^{1}H \) NMR, \(^{13}C \) NMR, HRSI-MS | Dealkylation; Dehydration; Oxidation | Metabolites: lower cytotoxic activities against human HepG2, NCI-H460, MCF-7 and HeLa cell lines than parent drug & MPD. However, M1 and M4 exhibited strong anti-cancer activities against HepG2 (M1), NCI-H460 cell lines (M4). | All metabolites: lower cytotoxic activities against human HepG2, NCI-H460, MCF-7 and HeLa cell lines than parent drug & MPD. However, M1 and M4 exhibited strong anti-cancer activities against HepG2 (M1), NCI-H460, and HeLa cell lines (M4). |

**Ref.** [54]
| Compound | Species | Method | In vivo | In vitro | Clinical trial | Comments |
|----------|---------|--------|---------|----------|---------------|----------|
| Oridonin (ORI) (Diterpinoid of Isodon rubescens) | Male Sprague-Dawley rats | UPLC-QqQ TOF-MS | Bile, urine | 17 Metabolites for bile (M1-M4, M6-M7); 10 Metabolites for urine (M1-M6, M8-M18) | UPLC-QqQ TOF-MS | Not evaluated |
| | Human hepatocellular carcinoma cell lines (HepG2) | HPLC-RD | - | 1 Metabolite (4) | - | Not evaluated |
| Quercetin (flavonoid) | Human cancer patients (IV: 10 mg) | UPLC-QqQ TOF-MS | Urine | 8 Fractions for urine (U1-U8); 10 Fractions for feces (F1-F10) | - | Not evaluated |
| | Rabectedin (ET-743: isolated compound from Ecteinascidia turbinata) | UPLC-QqQ TOF-MS | Urine and feces | 8 Fractions for urine (U1-U8); 10 Fractions for feces (F1-F10) (U4, F3, and ETM-204; U5 and F6, ETM-217; U7 and F8, ETM-759; U8 and F10; ETM-259 + acetate ester hydrolysis (ETM-217); | - | Not evaluated |
| Yuanhuapine (Isolated from Daphne genkwa) | Male Sprague-Dawley rats | UPLC-QqQ TOF-MS | Urine | 12 Metabolites (M1-M12) | - | Not evaluated |
Table 3 (Continued).

| Anticancer Drug          | Type of Study | Biochemical Tool/Animal/Human (Route: Dose) | Type of Sample | Analytical Technique | Outcome Metabolite | Metabolic Pathway                                                                 | Efficacy/Toxicity of Metabolite | Ref. |
|--------------------------|---------------|--------------------------------------------|----------------|---------------------|--------------------|----------------------------------------------------------------------------------|---------------------------------|------|
| Ziyuglycoside II         | In vitro      | Rat liver homogenate                       | --             | LC-QTOF-MS          | 16 metabolites (H-M1-H-M16)          | Glucuronidation (H-M1); Glucose conjugation (H-M2-H-M6); Dehydration + glucuronidation (H-M5); Formulation of ziyuglycoside II (adding CO: H-M6); Oxidation + reduction (H-M7); Dehydrogenation (H-M8); Demethylation (H-M9); Dehydration (H-M10, H-M11); Dearabinosylation + oxidation (H-M12, H-M13); Dearabinosylation (H-M14); Dearabinosylation + reduction (H-M15, H-M16) | Not evaluated                  | [83] |
|                          | In vivo       | Male Sprague-Dawley rats (Oral: 50 mg/kg)  | Urine, feces   | UFLC-QTOF-MS        | 10 Metabolites for urine (U-M1-U-M10); 10 Metabolites for feces (F-M1 and F-M10) | Glucuronidation + glycosylation (U-M1); Glucuronidation + deglycosylation + decarboxylation + dihydroxylation (U-M2); U-M2 + deoxidation + methylation (U-M3); Glucuronidation + loss of C,H,O (U-M4); U-M4 + deoxidation + methylation (U-M5); Decarboxylation (U-M7); Glucosylation (U-M6); Dearabinosylation (U-M9 and F-M9); Dearabinosylation + oxidation (U-M8, F-M5, F-M6); Dearabinosylation + dehydrogenation (U-M10); Oxidation (F-M1); F-M1 + dehydrogenation (F-M2); Dehydration (F-M3 and F-M4); Dearabinosylation + loss of CO (F-M7); Dearabinosylation + demethylation (F-M8); F-M9 + dehydrogenation (F-M10) |                                   |      |

Abbreviations: ESI, Electrospray Ionization; GC, Gas Chromatography; HLM, Human Liver Microsome; HPLC, High Performance Liquid Chromatography; HR, High Resonance; HRSI, High Resolution Single Ion; IP, Intraperitoneal; IV, Intravenous; LC, Liquid Chromatography; MS, Mass Spectrometry; MLM, Monkey Liver Microsome; NMR, Nuclear Magnetic Resonance spectroscopy; PO, Per oral; QqQ, Triple quadrupole; LIT, Linear Ion Trap; LSC, Liquid Scintillation Counting; QTOF, Quadrupole Time-of-flight; QTRAP, Linear ion trap Triple Quadrupole; R.D, Radio Detection; RLM, Rat Liver Microsome; RRLC, Rapid Resonance Liquid Chromatography; TIS, Turbo Ion Spray; TOF, Time-of-Flight; UHPLC, Ultra-high performance liquid chromatography; UPLC, Ultra Performance Liquid Chromatography; UV, Ultraviolet detection.
Table 4 Activities of Conventional Anticancer Drugs, Synthetic Anticancer Candidates, Small Molecules Targeted Therapy, Herb-Derived Compounds

| Compounds | References | Activity |
|-----------|------------|---------|
| AM6-36 (3-amino-6-(3′-aminopropyl)-5H-indeno[1,2-c]isoquinoline-5,11-(6H)-dione) | [13] | Antiproliferation (Breast cancer cell line (MCF-7)) |
| ARQ 501 (synthetic β-lapachone) | [15] | Anticancer (Pancreatic, head and neck cancer, and leiomysarcoma) |
| Cabazitaxel | [16] | Anticancer (Prostate cancer) |
| Capecitabine | [17] | Anticancer (Colorectal cancer) |
| Carbendazim | [18] | Apoptotic induction, Antitumor (Solid tumor) |
| CI-941 (losoxantrone) | [19] | Anticancer (Breast and prostate cancers) |
| CP-31398 (N′-[2-[2-(4-methoxyphenyl) ethenyl)-4-quinazolinyl]-N, N-dimethyl-1,3-propanediamine Dihydrochloride) | [84,85] | Antiproliferative (Colon cancer (DLD1) and lung cancer (H460) and intestinal tumor cells) |
| CPA (Cyproterone acetate) | [22] | Anticancer (Prostate cancer) |
| Cisplatin | [20] | Anticancer (Testicular, ovarian, bladder, cervical, esophageal, small cell lung, head and neck cancers) |
| Crisnatol | [23] | Antitumor (Hepatoma) |
| Cyclophosphamide | [24,86] | Anticancer (Leukemia, lymphoma, breast, lung, prostate, and ovarian cancers) |
| DFS (Trans-2,6-difluoro-4′-(N, N-dimethylamino) stilbene: Stilbene analog) | [25] | Antitumor (Colon cancer) |
| 5′-dFLud and 5′-dFUR (5′-deoxy-5-fluouridine) | [26,27] | Anticancer (Gastric, colorectal, and breast cancer) |
| EAPB0203 | [28] | Antitumor (Melanoma, T lymphoma, colon, and breast cancers) |
| EAPB0503 | [29] | Antitumor (Melanoma, T lymphoma, and colon cancer) |
| E-DE-BPH (E-3,4-bis (4-Ethylphenyl) hex-3-ene: stilbene derivatives) | | Anticancer |
| 2-F-araA (9-β-D-arabinofuranosyl-2-fluoradenine) | [31] | Antitumor (Leukemia) |
| Flutamide | [32] | Antiandrogen (Prostate cancer) |
| 4-Hydroxyanisole | [33] | Anticancer (Malignant melanoma) |
| Irinotecan | [34] | Anticancer (Colon and lung cancer) |
| Ixabepilone | [36] | Anticancer (Metastatic breast cancer) |
| JM216 | [37] | Antitumor (Human ovarian carcinoma cell model) |
| KO2 (Morpholine-urea-Phe-Hphe-vinylsulfone) | [38] | Inhibit cancer progress by inhibiting potent cysteine protease |
| Laromustine | [39] | Anticancer (Leukemia) |
| 2-Methoxyestradiol | | Anticancer (Metastatic breast cancer, prostate cancer, and various tumors) |
| Mitomycin C | [48] | Anticancer (Bladder, colon, and breast cancers) |
| NB-506 | [41,89] | Antitumor (lung and colon cancers, and metastatic cells) |
| (6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(b-D-glucopyranosil)-5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione) | | |
| 9NC (9-Nitro-20(S)-camptothecin) | [90] | Anticancer (Ovarian, tubal, and peritoneal cancer) |
| NSC 141549 (4′- (9-Acrinidylamino) methanesulfon-rn-aniside (rn -AMSA)) | [43] | Antitumor (L1210 leukemia and Lewis lung carcinoma) |
| NSC 652287 (2,5-bis(5-hydroxymethyl-2-thienyl) furan) | [44,91] | Antiproliferative (renal carcinoma cells) |
| NSC 674495 (2-(4-Amino-3-methylphenyl) benzothiazole: DF 203) | [45] | Antitumor (Breast cancer (MCF-7 and MDA 468) cells models) |
| PAC-1 (4-benzyl-piperazin-1-yl)-acetic acid (3-allyl-2-Hydroxy-benzylidene)-hydrazone | [46,92] | Antitumor (colon cancer cell models) |
| Paclitaxel | [47] | Anticancer (Breast, lung, head, neck, and ovarian cancers) |

(Continued)
Table 4 (Continued).

| Compounds                        | References | Activity                                                                                                                                 |
|----------------------------------|------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Phenylbutyrate                   | [93]       | Antitumor (Human prostate cancer, hepatocarcinoma and hepatoblastoma models), Anticancer (Acute myelogenous leukemia)                     |
| Phyllanthoside                   | [50]       | Antitumor (B16 melanoma and P388 leukemia)                                                                                                                                                       |
| Sepin-1                          | [51]       | Antiproliferative (Breast cancer, leukemia, and neuroblastoma), Antitumor (breast carcinoma), Apoptotic induction                           |
| SN30000 (3-(3-Morpholinopropyl)-7,8-dihydro-6H-indeno[5,6-e][1,2,4]triazine 1,4-dioxide: tirapazamine analog) | [6,94]     | Antiproliferative (Human colon cancer (HT29) and cervical (SiHa) cancer cells), Antitumor (HT29 and SiHa cancer cells models)               |
| Tamoxifen                        | [54,95]    | Antiestrogen (Breast cancer)                                                                                                                                                                       |
| TAS-102 (tipiracil hydrochloride (TPI) + trifluridine (FTD)) | [56]       | Anticancer (Metastatic colorectal cancer)                                                                                                                                                         |
| TNP-470 (O-(chloroacetyl-carbamoyl) fumagillol) | [57]       | Antitumor (B16 BL6 melanoma, M 5076 reticulum cell sarcoma, Lewis lung carcinoma, Walker 256 carcinoma), Anticancer, Antiangiogenesis        |
| TW01003 ((3E,6E)-3-Benzylidene-6-[[5-hydroxy pyridin-2-yl]methylene] piperazine-2,5-dione) | [58]       | Antitumor, Antiangiogenesis                                                                                                                                                                       |
| **Small molecules-targeted anticancer drugs** |            |                                                                                                                                           |
| AZD8055                          | [59]       | Antiproliferation, Apoptotic induction, and Migration reduction (Leukemia, cervical, breast cancer, and laryngeal carcinoma)           |
| Brivanib                         | [60,95]    | Anticancer (Hepatocellular carcinoma)                                                                                                                                                             |
| EPZ-5676 (pinometostat)          | [61]       | Anticancer (Leukemia)                                                                                                                                                                             |
| HM781-36B (1-[4-[4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yl]-piperidin-1-yl] prop-2-en-1-one hydrochloride) | [5]        | Anticancer (Advanced solid tumors i.e. non-small-cell lung cancer (NSCLC) patients with EGFR mutation (T790M), breast, and gastric cancer) |
| Imatinib                         | [62,63]    | Anticancer (Chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST))                                             |
| Irosustat                        | [64]       | Antitumor (Breast cancer model), Anticancer (Breast cancer)                                                                                                                                       |
| JNJ-38877605                     | [65]       | Antitumor (Prostate, non-small-cell lung, and gastric cancer and glioblastoma cells models)                                                                                                        |
| Lenvatinib                       | [66]       | Anticancer (Hepatocellular carcinoma, melanoma, renal carcinoma, non-small-cell lung carcinoma, glioblastoma multiforme, ovarian and endometrial carcinoma)   |
| Neratinib                        | [67]       | Anticancer (Breast cancer)                                                                                                                                                                         |
| ON 013100 ((E)-2,4,6-trimethoxystyril-3-hydroxy-4-methoxybenzyl sulfone (Kinase inhibitor)) | [68]     | Anticancer (Lymphoma and acute lymphoid leukemia)                                                                                                                                                |
| Osimertinib                     | [69]       | Anticancer (Non–small cell lung cancer)                                                                                                                                                          |
| Pimasertib                      | [70]       | Anticancer (Non-small cell lung, colorectal cancer, and head and neck squamous cell carcinoma)                                                                                                      |
| TKI258 (dovitinib)               | [96]       | Anticancer (Renal cell carcinoma, advanced breast cancer, relapsed multiple myeloma and urothelial cancer)                                                                                         |
| **Herb-derived compounds**       |            |                                                                                                                                           |
| Alantolactone (Inula helenium L.) | [9]        | Antitumor (Liver cancer cells model)                                                                                                                                                             |
| Astragali Radix (water extract)  | [71]       | Apoptotic induction                                                                                                                                                                               |
| Calphostin C (Cladosporium cladosporoides) | [72] | Antitumor (Leukemia model), apoptotic induction                                                                                                                                               |
| CAT (3,6,7-trimethoxyphenan-throindolizidine (isolated from Tylophora atrapliculata)) | [73] | Antitumor                                                                                                                                                                                        |
| Dimethoxycurcumin (Curcumin analog) | [74] | Antiproliferation and apoptosis induction (Human colon (HCT116) cancer cells model)                                                                                                          |

(Continued)
In rat liver, the expression level of CYP2C12 is higher in females than males, while the level of CYP2C11 is higher in males than females.

Ventura et al investigated the metabolic profiles of irosustat (inhibitor of steroid sulfatase under development for hormone-sensitive cancers such as breast and prostate cancer) using liver microsomes from male and female rats, dogs, monkeys, and humans. In rats, 11 metabolites (designated M7-M11, M13-M16, M18 and 667-coumarin) were detected in both genders, while 1 different metabolite each was detected in males (P-24) and females (P-36). Eight similar metabolites (P-14, M7-M10, M13, M16, and P-24) were detected in both genders of monkeys, whereas only M14 metabolite was detected in only male monkeys. In dogs and humans, similar 14 metabolites were detected in both genders. These results suggest that the metabolites generated from the parent anticancer drugs/candidate compounds may vary depending on the expression levels of the responsible metabolizing enzymes in each gender.

**Route of Administration**

Route of administration was found to be one contributing factor that influences the metabolite profiles of anticancer drugs/candidate compounds. Following intravenous administration of TW-01003 (a piperazinedione derivative designed as an antimitotic agent), the major metabolite (TW-01003 sulfate) was detected in rat plasma. Following oral administration, on the other hand, TW-01003 glucuronide became major metabolite. This might be due to the enterohepatic recirculation, which increases the level of glucuronide conjugates in the systemic circulation. In another metabolism study of tamoxifen (selective estrogen-receptor modulator for breast cancer), however, two similar metabolites (4-hydroxytamoxifen and N-desmethyltamoxifen) were detected in mouse serum following both oral and subcutaneous routes of administration.

**Dose**

The dose level of anticancer drugs/candidate compounds was not found to be the major factor that influenced their metabolite profiles, but the metabolite levels. In the study of tamoxifen metabolism in mice, higher levels of metabolites were reported after an oral dose of 200 compared with 50 mg/kg/day. In the study of JM 216 or satraplatin, a platinum drug, the number of metabolites detected was similar among patients receiving different doses of the compound.
(120, 200, 300, 420, and 540 mg/m²). Plasma levels of each metabolite were not significantly different in patients who received different doses of the drug. For example, metabolite A was detected at 20–58.9% for 120 mg/m², 10.2–50% for 200 mg/m², 8.7–76.2% for 300 mg/m², 8.2–85.9% for 420 mg/m², and 5.1–44.4% for 540 mg/m². Such broad range of metabolite levels in plasma observed in patients receiving the same dose might be due to inter-individual variability metabolizing enzyme(s) responsible for JM216 metabolism in each patient. These results suggest that the metabolite profiles of anticancer drugs/candidate compounds are not completely affected by the dose of administration but may be influenced by the dose level and duration of administration.

**Contribution of Metabolites to Anticancer Activity and Toxicity of Anticancer Drugs/Candidate Compounds**

The metabolites generated from the parent anticancer drugs/candidate compounds can be both active and inactive metabolites. This information is essential for cancer chemotherapy with a narrow therapeutic window, particularly in individuals with increased or decreased drug-metabolizing enzyme activities influenced by genetic and nongenetic factors. Several studies showed that biotransformation could significantly influence the activity and toxicity of the anticancer drugs/candidate compounds. The metabolites of some active drugs/compounds exhibited more potent anticancer activity than their parent compounds. For example, the cytotoxic activity of the M3 metabolite of fisetin, a plant polyphenol, against Lewis carcinoma (LLC) cell line was shown to be about 2-fold of fisetin itself (IC₅₀ or 50% inhibitory concentrations of 24 vs. 59 µM). However, both M3 and fisetin exhibited similar cytotoxic activities against the endothelial EAhy 926 cell line (IC₅₀ 72 vs. 76 µM). It was noted however, that the cytotoxic activity of this metabolite against the normal cell line, NIH 3T3, was relatively higher than fisetin (IC₅₀ 128 vs. 195 µM). The M1 and M2 metabolites of the synthetic compound irisflorin were shown to exhibit more potent cytotoxic activity against human prostate cancer (DU145) and breast cancer (MCF-7) cell lines compared with the parent drug (IC₅₀ 65.12 vs. 35.71 vs. >300 µM and 74.17 vs. 36.30 vs. >300 µM, respectively). The metabolite of a potent antileukemic compound, phyllanthoside, also exhibited lower cytotoxic activity against human rhabdomyosarcoma A204 cell line compared with the parent compound (IC₅₀ 24 µM and 0.47 nM, respectively). Some metabolites showed low or no cytotoxic activity. For example, The metabolite 6c of NSC 674495, an antitumor 2-(4-Aminophenyl) benzothiazoles, exhibited low cytotoxic activity against MCF-7 cell line (IC₅₀>100 M) and was not shown to be an active metabolite. The anticancer activities of the metabolites of these compounds should be further investigated in animals and humans to confirm their activities in vivo. Some metabolites may be pharmacologically inactive, while some may exhibit toxicity in animal models. For examples, 2-F-araH, the metabolite of 2-F-araA and the antitumor 9-β-D-arabinofuranosyl-2-fluoroadenine exhibited no antitumor activity in BDF1 mice bearing L1210 leukemia cells following 200 mg/kg intraperitoneal dosing for nine days. The M1 to M5 metabolites of JNJ-38877605 (a potent and selective Met receptor tyrosine kinase inhibitor) were shown to be associated with crystal formation in the kidney. The M10 metabolite, on the other hand, was shown to be the toxic metabolite found in humans (at sub-therapeutic dose 60 mg OD) and rats and was also noted as a species-specific toxic metabolite. Since renal toxicity could be observed even at a subtherapeutic dose, this toxicity is also likely to be observed at standard dose. The M14 metabolite of the tirapazamine analog SN30000 was found to be the cause of acute toxicity (hypothermia) similarly to the parent drug after the administration at the maximum tolerated dose (MTD: 186 mg/kg SN30000). However, hypothermia was also observed at 50% of MTD. Thus, this toxicity can be observed at the therapeutic dosage (75% of MTD).

**Conclusion**

Drug metabolism plays a critical role in determining the pharmacological and toxicological effects of a drug in human. Metabolite profiling study is essential in determining therapeutic efficacy and toxicity of anticancer drugs/compounds from both chemical synthesis or natural sources. The generated metabolite profiles, either the types and amounts can be significantly influenced by factors such as species, gender, and route and dose of administration. Moreover, the metabolites can be both active and toxic metabolites, and some metabolites are inactive. The information of metabolite profile wills provides beneficial knowledge in anticancer agent development to improve anticancer activity and safety profiles of anticancer drugs or drug candidates.

**Acknowledgments**

The authors would like to thank the Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma (Thammasat University), Chulabhorn
International College of Medicine (Thammasat University), and Drug Discovery and Development Center (Thammasat University) for providing all the necessary support in conducting this systematic review.

**Author Contributions**
Nadda Muhamad: Conception and design, data analysis and interpretation, drafting the article, final approval, agreement to be accountable for the accuracy or integrity of the work.

Kesara Na-Bangchang: Conception and design, data analysis and interpretation, revising the article, final approval, agreement to be accountable for the accuracy or integrity of the work.

**Funding**
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Disclosure**
The authors report no conflicts of interest in this work.

**References**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492

2. Barth T, Habenschus MD, Lima Moreira F, Ferreira Lde S, Lopes NP, Moraes de Oliveira AR. In vitro metabolism of the lignan (-)-grandisatin, an anticancer drug candidate, by human liver microsomes. Drug Test Anal. 2015;7(9):780–786. doi:10.1002/dta.1743

3. Chen Y, Guo J, Tang Y, et al. Pharmacokinetic profile and metabolite identification of yuhanuapine, a bioactive component in Daphne genkwa by ultra-high performance liquid chromatography coupled with tandem mass spectrometry. J Pharm Biomed Anal. 2015;112:60–69. doi:10.1016/j.jpba.2015.04.023

4. Dubbelman AC, Uphaugove A, Beijnen JH, et al. Disposition and metabolism of 1H-C-dovitinib (TK1258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012;70(5):653–663. doi:10.1007/s00058-012-1947-2

5. Kim E, Kim H, Suh K, et al. Metabolite identification of a new tyrosine kinase inhibitor, HM781-36, and a pharmacokinetic study by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2013;27(11):1183–1195. doi:10.1002/rcm.6559

6. Gu Y, Chang TT, Wang J, et al. Reductive metabolism influences the toxicity and pharmacokinetics of the hypoxia-targeted benzotrazine di-oxide anticancer agent SN30000 in mice. Front Pharmacol. 2017;8:531. doi:10.3389/fphar.2017.00531

7. Shrestha R, Jo JJ, Lee D, Lee T, Lee S. Characterization of in vitro and in vivo metabolism of leclamine using liquid chromatography-tandem mass spectrometry. Xenobiotica. 2019;49(5):577–583.

8. Na-Bangchang K, Plengsuriyakarn T, Karbwang J. Research and development of Atractylodes lancea (Thunb) DC, as a promising candidate for cholangiocarcinoma chemotherapeutics. J Evid Based Complementary Altern Med. 2017;2017:16.

9. Yao D, Li Z, Huo C, et al. Identification of in vitro and in vivo metabolites of alantolactone by UPLC-TOF-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1033–1034:250–260. doi:10.1016/j.jchromb.2016.08.034

10. Elhassan G. Drug development: stages of drug development. J Pharmcovicul. 2015;5:3.

11. Gunaratna C. Drug metabolism and pharmacokinetics in drug discovery: a primer for bioanalytical chemists, part I. Curr Sep. 2000;19(1):17–23.

12. Gonzalez FJ, Tukey RH. Drug Metabolism. 11th ed. New York: McGraw Hills; 2006.

13. Chen L, Conda-Sheridan M, Reddy PV, et al. Identification, synthesis, and biological evaluation of the metabolites of 3-amino-6-(3’-aminopropyl)-5H-indeno[1,2-c]soquinoline-5,11-(6H)dione (AM6-36), a promising renoxin lead compound for the development of cancer chemotherapeutic and chemopreventive agents. J Med Chem. 2012;55(12):5965–5981.

14. Miao XS, Song P, Savage RE, et al. Identification of the in vitro metabolites of 3,4-dihydro-2,2-dimethyl-2H-naphthof[1,2-b]pyran-5,6-dione (ARQ 501; beta-lapachone) in whole blood. Drug Metab Dispos. 2008;36(4):641–648. doi:10.1124/dmd.107.018572

15. Savage RE, Tyler AN, Miao XS, Chan TC. Identification of a novel glucosylsulfate conjugate as a metabolite of 3,4-dihydro-2,2-dimethyl-2H-naphthof[1,2-b]pyran-5,6-dione (ARQ 501; beta-lapachone) in mammals. Drug Metab Dispos. 2008;36(4):753–758. doi:10.1124/dmd.107.018655

16. Ridoux L, Semiond DR, Vincent C, et al. A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors. Anticancer Drugs. 2015;26(3):350–358. doi:10.1097/CAD.0000000000001858

17. Desmoulin F, Gilard V, Martino R, Malet-Martino M. Isolation of a novel metabolite of capetibamine, an oral 5-fluorouracil produrg, and its identification by nuclear magnetic resonance and liquid chromatography-tandem mass spectrometry as a glucuron conjugate of 5’-deoxy-5-fluorocytidine, namely 2’-[(beta-D-glucuronic acid)-5’-deoxy-5-fluorocytidine. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;792(2):323–332. doi:10.1016/s1570-0232(03)00319-2

18. Jia L, Wang H, Wang Y, Garza M, Weitman SD. Carbendazim: disposition, cellular permeability, metabolite identification, and pharmacokinetic comparison with its nanoparticle. J Pharm Sci. 2003;92(1):161–172. doi:10.1016/j.jpsts.2002.10.072

19. Renner UD, Piperopoulos G, Gebhardt R, Ehninger G, Zeller KP. The oxidative biotransformation of losoxantrone (CI-941). Drug Metab Dispos. 2002;30(4):464–478. doi:10.1124/dmd.30.4.464

20. Bandu R, Alun HS, Lee JW, et al. Liquid chromatography-electrospray ionization tandem mass spectrometric (LC/ESI-MS/MS) study for the identification and characterization of in vivo metabolites of cisplatin in rat kidney cancer tissues: online hydrogen/deuterium (H/D) exchange study. PLoS One. 2015;10(8):e0134027. doi:10.1371/journal.pone.0134027

21. Johnson WD, Muzzio M, Detrisac CJ, Kapetanovic IM, Kopelovich L, McCormick DL. Subchronic oral toxicity and metabolite profiling of the p53 stabilizing agent, CP-31398, in rats and dogs. Toxicology. 2011;289(2):141–150. doi:10.1016/j.tox.2011.08.009

22. Kerdar RS, Baumann A, Brudny-Kloppel M, Biere H, Blode H, Kuhnz W. Identification of 3 alpha-hydroxy-cypoteronace acetate as a metabolite of cypoteronate acetate in the bile of female rats and the potential of this and other already known or putative metabolites to form DNA adducts in vitro. Carcinogenesis. 1995;16(8):1835–1841. doi:10.1093/carcin/16.8.1835

23. Patel DK, Shockcor JP, Chang SY, Sigel CW, Huber BE. Metabolism of a novel antitumor agent, crisnatol, by a human hepatoma cell line, Hep G2, and hepatic microsomes. Characterization of metabolites. Biochem Pharmacol. 1991;42(2):337–346. doi:10.1016/0006-2952(91)90721-G
24. Fenselau C, Kan MN, Billets S, Colvin M. Identification of phosphorodiamidic acid mustard as a human metabolite of cyclophosphamide. Cancer Res. 1975;35(6):1453–1457.

25. Yeo SC, Srivira VM, Huang M, et al. Analysis of trans-2,6-difuoro-4′-(N,N-dimethylamino)stilbene (DFS) in biological samples by liquid chromatography-tandem mass spectrometry: metabolite identification and pharmacokinetics. Anal Bioanal Chem. 2015;407(24):7319–7332. doi:10.1007/s00216-015-8893-x

26. Malet-Martino MC, Martino R, Lopez A, et al. New approach to metabolism of 5′-deoxy-5-fluorouridine in humans with fluorine-19 NMR. Cancer Chemother Pharmacol. 1994;33(1):31–35. doi:10.1007/BF03401143

27. Zambonin CG, Palmisano F. Gas chromatography-mass spectrometry identification of a novel N3-methylated metabolite of 5′-deoxy-5-fluorouridine in plasma of cancer patients undergoing chemotherapy. J Pharm Biomed Anal. 1996;14(11):1521–1528. doi:10.1016/0731-7085(96)01798-0

28. Lafliffe F, Banaigs B, Ingumbert N, et al. Characterization of a new anticancer agent, EAPB0203, and its main metabolites: nuclear magnetic resonance and liquid chromatography-mass spectrometry studies. Anal Chem. 2012;84(22):9865–9872. doi:10.1021/ac3021483

29. Lafliffe F, Solassol I, Enjalbal C, et al. Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2014;88:429–440. doi:10.1016/j.jpba.2013.09.015

30. Fabian EJ, Metzler M. Selective metabolism of E-3,4-bis(4-ethyl-phenyl)hex-3-ene in rat liver microsomes. Arch Toxicol. 2006;80(1):17–26. doi:10.1007/s00204-005-0067-7

31. Struck RF, Shortacy AT, Kirk MC, et al. Identification of metabolites of 9-beta-D-arabinofuranosyl-2-fluorodeoxyadenine, an antitumor and antiviral agent. Biochem Pharmacol. 1982;31(11):1975–1978. doi:10.1016/0006-2952(82)90407-5

32. Tevell A, Lennernas H, Jonsson M, et al. Flutamide metabolism in the athymic mouse for the study of antitumor victim and perpetrator potential of the anticancer agent laromustine. J Steroid Biochem Mol Biol. 2007;109(3):425–434. doi:10.1016/j.jsbmb.2007.03.017

33. Pavel S, Holden JL, Riley PA. Metabolism of 4-hydroxyanisole: identification of major urinary excretory products. Pigment Cell Res. 1989;2(5):421–426. doi:10.1111/j.1111.1989.2.issue-5

34. Santos A, Zanetta S, Cresteil T, et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Arch Toxicol. 2001;75(8):475–482. doi:10.1007/s00218-001-0318-2

35. Nilgün Çömezoglu, Evez H, Szekely I, et al. Characterization of metabolites of the new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-beta-D-glucopyranosil)SH-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites. Drug Metab Dispos. 1999;27(2):205–212.

36. Li K, Chen X, Zhong D, Li Y. Identification of the metabolites of 9-nitro-20(S)-camptothecin in rats. Drug Metab Dispos. 2003;31(6):792–797. doi:10.1021/dm3107692

37. Przybylski M, Czyryk RL, Shoemaker D, Adamson RH. Identification of conjugation and cleavage products in the thiolactic metabolism of the anticancer drug 4′-(9-acridinylamino)methanesulfon-m-anisidine. Biomed Mass Spectrom. 1981;8(10):485–491. doi:10.1002/bms.1200810104

38. Phillip LR, Jorden JL, Rivera MI, Wolfe TL, Upadhyay K, Stinson SF. Identification of the major metabolite of 2,5-bis(5-hydroxyethyl-2-thienyl)furran (NSC 652287), an antitumor agent, in the S9 subcellular fraction of dog liver cells. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;767(1):27–33. doi:10.1016/S0731-7085(01)00530-8

39. Kishiyama E, Hutchinson I, Chua MS, et al. Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-nitro-oxidation products of antitumor 2-(4-aminobenzyl)benzothiazoles. J Med Chem. 1999;42(20):4172–4184. doi:10.1021/jm9901040

40. Ren L, Bi K, Gong P, et al. Characterization of the in vivo and in vitro metabolic profile of PAC-1 using liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;876(1):47–53. doi:10.1016/j.jchromb.2008.10.006

41. Royer I, Alvinerie P, Armand JP, Ho LK, Wright M, Monsarrat B. Paclitaxel metabolites in human plasma and urine: identification of 6-alpha-hydroxypaclitaxel, 7-epitaxol and taxol hydrolysis products using liquid chromatography-atmospheric-pressure chemical ionization mass spectrometry. Rapid Commun Mass Spectrom. 1999;9(6):495–502. doi:10.1002/rem.290090605

42. Bun SS, Giacometti S, Fanciullino R, Ciccolini J, Bun H, Aubert C. Effect of several compounds on biliary excretion of paclitaxel and its metabolites in guinea-pigs. Anticancer Drugs. 2005;16(6):675–682. doi:10.1016/j.acdbio.2005.07.00013

43. Comte B, Kasumov T, Pierce BA, et al. Identification of phenylbutyrylglutamate, a new metabolite of phenylbutyrate metabolism in humans. J Mass Spectrom. 2002;37(6):581–590. doi:10.1002/jms.316

44. Chapman DE, Moore DJ, Melder DC, Breau A, Powis G. Isolation, identification and biological activity of a phyllanthoside metabolite produced in vitro by mouse plasma. Cancer Chemother Pharmacol. 1989;25(3):184–188. doi:10.1007/BF00689580

45. Li F, Zhang N, Gorantla S, Gilbertson SR, Pati D. The metabolism of separate inhibitor sepin-1 in human, mouse, and rat liver microsomes. Front Pharmacol. 2018;9:313. doi:10.3389/fphar.2018.00313

46. Robinson SP, Langan-Fahey SM, Jordan VC. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur J Cancer Clin Oncol. 1989;25(12):1769–1776. doi:10.1016/0727-3379(89)90347-7

47. Poon GK, Walter B, Lonning PE, Horton MN, McCague R. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab Dispos. 1995;23(3):377–382.

48. Kisangwa ER, Moi LLH, Gjerde J, Mollvig G, Lien EA. Induction of hepatic drug-metabolising enzymes and tamoxifen metabolite profile in relation to administration route during low-dose treatment in nude rats. J Steroid Biochem Mol Biol. 2005;94(5):489–498. doi:10.1016/j.jsbmb.2004.12.037
55. Dahmene E, Boccard J, Csajka C, et al. Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology. *Anal Bioanal Chem.* 2014;406(11):2627–2640. doi:10.1007/s00216-014-7682-2

56. Lee JJ, Seraj J, Yoshida K, et al. Human mass balance study of TAS-102 using (14C) analyzed by accelerator mass spectrometry. *Cancer Chemother Pharmacol.* 2016;77(3):515–526. doi:10.1007/s00280-016-2965-2

57. Placidì L, Cretton-Scott E, de Sousa G, Rahmani R, Placidì M, Sommadossi JP. Disposition and metabolism of the angiogenic modulator O-(chloroacetyl-carbamoyl) fumagillo (TNP-470; AGM-1470) in human hepatocytes and tissue microsomes. *Cancer Res.* 1995;55(14):3036–3042.

58. Wang CL, Chen CK, Wang YH, Cheng YW. In search of the active metabolites of an anticancer piperazinedione, TW01003, in rats. *Biomed Res Int.* 2014;2014:793504.

59. Rashid MM, Oh HA, Lee H, Jung BH. Metabolite identification of AZD8055 in Sprague-Dawley rats after a single oral administration using ultra-performance liquid chromatography and mass spectrometry. *J Pharm Biomed Anal.* 2017;145:473–481. doi:10.1016/j.jpba.2017.06.059

60. Gong J, Gan J, Iyer RA. Identification of the oxidative and conjugative enzymes involved in the biotransformation of brivanib. *Drug Metab Dispos.* 2012;40(1):219–226. doi:10.1124/dmd.111.042457

61. Waters NJ, Smith SA, Olhava EJ, et al. Metabolism and disposition of the DOTIL inhibitor, pinometostat (EPZ-5676), in rat, dog and human. *Cancer Chemother Pharmacol.* 2016;77(1):43–62. doi:10.1007/s00280-015-2929-y

62. Marull M, Rochat B. Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometers. *J Mass Spectrom.* 2006;41(3):390–404. doi:10.1002/jms.1002

63. Rochat B, Fayet A, Widner N, et al. Imatinib metabolism profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry. *J Mass Spectrom.* 2008;43(6):736–752. doi:10.1002/jms.1369

64. Ventura V, Sola J, Celma C, Peraire C, Obach R. In vitro metabolism of irusmut, a novel steroid sulfatase inhibitor: interspecies comparison, metabolite identification, and metabolic enzyme identification. *Drug Metab Dispos.* 2011;39(7):1235–1246. doi:10.1124/dmd.111.038315

65. Lolkema MP, Bohets HH, Arkenau HT, et al. The c-Met tyrosine kinase inhibitor 3,6,7-trimethoxyphenanthroindolizidine in rat urine. *Anal Chim Acta.* 2015;837. doi:10.1016/j.aca.2012.04.024

66. Touil YS, Auzeil N, Boulinguez F, et al. Disposition and metabolism of the angiogenic agent 3,6,7-trimethoxyphenanthroindolizidine in rat. *Anal Chim Acta.* 2012;731:515–526. doi:10.1016/j.aca.2012.04.024

67. Liu W, Li S, Wu Y, et al. Metabolic profiling of methyl orientin by rat liver microsomes using high-performance liquid chromatography-electrospray ionization mass spectrometry and nuclear magnetic resonance spectra. *J Pharm Biomed Anal.* 2013;86:161–168. doi:10.1016/j.jpba.2013.08.008

68. Chen C, Lou Y, Wu Y, et al. Characterization of in vitro and in vivo metabolites of furanodiene in rats by high performance liquid chromatography-electrospray ionization mass spectrometry and nuclear magnetic resonance spectra. *Biochem Pharmacol.* 2016;90(6):825–837. doi:10.1016/j.bcp.2015.10.006

69. Jia YW, Zeng ZQ, Shi HL, et al. Characterization of in vitro metabolites of irusmut in rat liver microsomes using high-performance liquid chromatography coupled with tandem mass spectrometry. *Biomed Chromatogr.* 2016;30(9):1363–1370. doi:10.1002/bmc.3692

70. Chen M, Lou Y, Wu Y, et al. Characterization of in vivo and in vitro metabolites of furodione in rats by high performance liquid chromatography-electrospray ionization mass spectrometry and nuclear magnetic resonance spectra. *J Pharm Biomed Anal.* 2013;86:161–168. doi:10.1016/j.jpba.2013.08.008

71. He X, Qiao A, Wang X, et al. Structural identification of methyl protodioscin metabolites in rats' urine and their antiproliferative activities against human tumor cell lines. *Streptoids.* 2006;7(1):829–833. doi:10.1016/j.streptoids.2006.05.013

72. Tian T, Jin Y, Ma Y, et al. Identification of metabolites of oridonin in rats with a single run on UPLC-triple-TOF-MS/MS system based on multiple mass defect filter data acquisition and multiple data processing techniques. *J Chromatogr A Analyt Technol Biomed Life Sci.* 2015;1006:80–92. doi:10.1016/j.chroma.2015.10.006

73. Boulton DW, Walle UK, Walle T. Fate of the flavonoid quercetin in human cell lines: chemical instability and metabolism. *J Pharm Pharmacol.* 1999;51(3):353–359. doi:10.1211/0022357991772167

74. Emmer JR, Rademaker-Lakhai JM, Rosing H, et al. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer. *Cancer Chemother Pharmacol.* 2007;59(6):825–837. doi:10.1007/s00280-006-0342-2

75. Xiao J, Chen H, Fu H, et al. Development of a novel sectional multiple filtering scheme for rapid screening and classifying metabolites of zizyphusoides II in rat liver and excreta specimen based on high-resolution mass spectrometry. *J Pharm Biomed Anal.* 2016;129:310–319. doi:10.1016/j.jpba.2016.06.053

76. Takimoto R, Wang W, Dicker DT, Rastinejad F, Lyssikatos J, el-Deiry WS. The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis. *Cancer Biol Ther.* 2002;1(1):47–55. doi:10.4161/cbt.1.1.41
85. Rao CV, Swamy MV, Patlolla JMR, Kopelovich L. Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice. Cancer Res. 2008;68(18):7670–7675. doi:10.1158/0008-5472.CAN-08-1610
86. Nicol BM, Prasad S. The effects of cyclophosphamide alone and in combination with ascorbic acid against murine ascites Dalton’s lymphoma. Indian J Pharmacol. 2006;38(4):260–265. doi:10.4103/0019-5049.27022
87. Cobham MV, Donovan D. Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer. Cancer Manag Res. 2009;1:69–77. doi:10.2147/CMAR.S5723
88. Snodgrass RG, Collier AC, Coon AE, Pritsos CA. Mitomycin C inhibits ribosomal RNA: a novel cytotoxic mechanism for bioreductive drugs. J Biol Chem. 2010;285(25):19068–19075. doi:10.1074/jbc.M109.040477
89. Ren J, Bailly C, Chaires JB. NB-506, an indolocarbazole topoisomerase I inhibitor, binds preferentially to triplex DNA. FEBS Lett. 2000;470(3):355–359. doi:10.1016/S0014-5793(00)01335-1
90. Verschraegen CF, Gupta E, Loyer E, et al. A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. Anticancer Drugs. 1999;10(4):375–383. doi:10.1007/10900-00001831-199904000-00005
91. Rivera MI, Stinson SF, Vistica DT, Jorden JL, Kenney S, Sausville EA. Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism. Biochem Pharmacol. 1999;57(11):1283–1295. doi:10.1016/S0006-2952(99)00046-5
92. Puth KS, Chen GW, Pearson JM, et al. Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol. 2006;2(10):543–550. doi:10.1038/nchembio814
93. Al-Keilani MS, Al-Sawalha NA. Potential of phenylbutyrate as adjuvant chemotherapy: an overview of cellular and molecular anticancer mechanisms. Chem Res Toxicol. 2017;30(10):1767–1777. doi:10.1021/acs.chemrestox.7b00149
94. Hicks KO, Siim BG, Jaiswal JK, et al. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin Cancer Res. 2010;16(20):4946. doi:10.1158/1078-0432.CCR-10-1439
95. Park JW, Finn RS, Kim JS, et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2011;17(7):1973–1983. doi:10.1158/1078-0432.CCR-10-2011
96. Hasinoff BB, Wu X, Nittiss JL, Kanagasabai R, Yalowich JC. The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochem Pharmacol. 2012;84(12):1617–1626. doi:10.1016/j.bcp.2012.09.023
97. Cortez AP, Menezes EGP, Bentifica PL, et al. Grandisind induces apoptosis in leukemic K562 cells. Braz J Pharm Sci. 2017;53(1).
98. Hashemzaei M, Delarami Far A, Yari A, et al. Anticancer and apoptosis-inducing effects of quercetin in vitro and in vivo. Oncol Rep. 2017;38(2):819–828. doi:10.3892/or.2017.5766
99. Martignoni M. Species and Strain Differences in Drug Metabolism in Liver and Intestine. s.n.; 2006:136.
100. Sakuma T, Kawasaky Y, Jarkamjorn K, Nemoto N. Sex differences of drug-metabolizing enzyme: female predominant expression of human and mouse cytochrome P450 3A isoforms. J Drug Metab Toxicol. 2012;3(3):325–337.
101. Mugford CA, Kedderis GL. Sex-dependent metabolism of xenobiotics. Drug Metab Rev. 1998;30(3):441–498. doi:10.3109/03602539808996322